0001575705-16-000133.txt : 20160520 0001575705-16-000133.hdr.sgml : 20160520 20160520115544 ACCESSION NUMBER: 0001575705-16-000133 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160520 DATE AS OF CHANGE: 20160520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: True Nature Holding, Inc. CENTRAL INDEX KEY: 0000802257 STANDARD INDUSTRIAL CLASSIFICATION: COMMUNICATIONS EQUIPMENT, NEC [3669] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53601 FILM NUMBER: 161665270 BUSINESS ADDRESS: STREET 1: 1355 PEACHTREE STREET STREET 2: SUITE 1150 CITY: ATLANTA STATE: GA ZIP: 30309 BUSINESS PHONE: 404-254-6980 MAIL ADDRESS: STREET 1: 1355 PEACHTREE STREET STREET 2: SUITE 1150 CITY: ATLANTA STATE: GA ZIP: 30309 FORMER COMPANY: FORMER CONFORMED NAME: Trunity Holdings, Inc. DATE OF NAME CHANGE: 20120125 FORMER COMPANY: FORMER CONFORMED NAME: BRAIN TREE INTERNATIONAL INC DATE OF NAME CHANGE: 19860922 10-Q 1 tnty_1q16.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarter Ended March 31, 2016

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________

Commission File Number 000-53601

TRUE NATURE HOLDING, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		87-0496850

(State or other jurisdiction of incorporation)		(I.R.S. Employer Identification Number)

1355 Peachtree Street, Suite 1150

Atlanta, Georgia 30309

(Address, including zip code, of principal executive offices)

Trunity Holdings, Inc.

12555 Orange Drive, Suite 202

Davie, Florida 33330

(Former name or former address if changed since last report.)

(404) 254-6980

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

☐	LARGE ACCELERATED FILER	☐	ACCELERATED FILER

☐	NON-ACCELERATED FILER	☒	SMALLER REPORTING COMPANY

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Indicate by check mark whether the registrant filed all documents and reports required to be filed by Section 12, 13, or 15(d) of the Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☐ No ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. YES ☐ NO ☒

As of May 19, 2016, 12,500,000 shares of the registrant’s common stock, $0.01 par value, were outstanding.

DOCUMENTS INCORPORATED BY REFERENCE: None

TRUE NATURE HOLDING, INC.

TABLE OF CONTENTS

		PAGE
PART I	FINANCIAL INFORMATION	3

Item 1.	Consolidated Financial Statements (Unaudited)	3

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	19

Item 4.	Controls and Procedures	19

PART II	OTHER INFORMATION	20

Item 1.	Legal Proceedings	20

Item 1A.	Risk Factors	20

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20

Item 3.	Defaults Upon Senior Securities	21

Item 4.	Mine Safety Disclosures	21

Item 5.	Other Information	21

Item 6.	Exhibits	22

	Signatures	26

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements

TRUE NATURE HOLDING, INC.

Consolidated Balance Sheets

	March 31,			December 31,
	2016			2015
	(unaudited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	17,881		$	28,185
Prepaid expenses		11,348			—
Prepaid expenses - related party		4,250			17,000
Total current assets		33,479			45,185

TOTAL ASSETS	$	33,479		$	45,185

LIABILITIES
Current liabilities
Accounts payable	$	471,201		$	414,463
Accrued interest		18,812			14,918
Accrued liabilities		63,465			13,325
Convertible note payable, net of discount		29,598			—
Debentures payable		122,167			122,167
Total current liabilities		705,243			564,873

TOTAL LIABILITIES		705,243			564,873

Commitments and Contingencies (Note 10)

STOCKHOLDERS’ DEFICIT
Preferred stock, $0.01 par value - 10,000,000 shares authorized, none issued and outstanding as of March 31, 2016 and December 31, 2015		—			—
Common stock, $0.01 par value – 500,000,000 shares authorized, 12,400,000 shares issued and outstanding at March 31, 2016; $0.01 par value – 500,000,000 shares authorized, 11,765,000 shares issued and outstanding at December 31, 2015		124,000			117,650
Additional paid-in capital		684,078			3,917
Accumulated deficit		(1,479,842	)		(641,255	)
Total Stockholders’ Deficit		(671,764	)		(519,688	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	33,479		$	45,185

The accompanying notes are an integral part of the Consolidated Financial Statements.

TRUE NATURE HOLDING, INC.

Unaudited Consolidated Statements of Operations and Comprehensive Loss

	For the Three Months Ended
	March 31,			March 31,
	2016			2015
Net Sales	$	—		$	—
Cost of sales		—			—
Gross Profit		—			—

Operating Expenses:
Research and development		—			—
Selling, general and administrative		832,369			—
Total operating expenses		832,369			—

Operating Loss from Continuing Operations		(832,369	)		—
Interest expense, net		(6,218	)		—
Loss From Continuing Operations before Income Taxes		(838,587	)		—
Provision for income taxes		—			—
Net Loss From Continuing Operations	$	(838,587	)	$	—

Discontinued Operations (Note 4):
Net Loss from discontinued operations, net of tax		—			(622,470	)
Other comprehensive loss, net of tax		—			(1,275	)
Comprehensive Loss from Discontinued Operations	$	—		$	(623,745	)

Net Loss	$	(838,587	)	$	(622,470	)
Comprehensive Net Loss	$	(838,587	)	$	(623,745	)


Net Loss from Continuing Operations Per Share – Basic and Diluted	$	(0.07	)	$	—
Net Loss from Discontinued Operations Per Share – Basic and Diluted	$	—		$	(1.15	)
Net Loss Per Share – Basic and Diluted	$	(0.07	)	$	(1.15	)

Weighted Average Number of Shares Outstanding During the Period - Basic and Diluted		12,057,500			542,605

The accompanying notes are an integral part of the Consolidated Financial Statements.

TRUE NATURE HOLDING, INC.

Unaudited Consolidated Statements of Changes in Stockholders’ Deficit

	Common Shares		Common Stock		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders’ Deficit
Balance at December 31, 2015		11,765,000	$	117,650	$	3,917	$	(641,255	)	$	(519,688	)
Sale of common stock, net of issuance cost		120,000		1,200		52,800		—			54,000
Shares issued to board members and consultants		500,000		5,000		582,500					587,500
Common stock issued for convertible note payable		15,000		150		16,213		—			16,363
Discount related to issuance of note payable and allocated fair value to beneficial conversion feature		—		—		16,364		—			16,364
Stock compensation expense		—		—		12,284		—			12,284
Net loss		—		—		—		(838,587	)		(838,587	)
Balance at March 31, 2016		12,400,000	$	124,000	$	684,078	$	(1,479,842	)	$	(671,764	)

The accompanying notes are an integral part of the Consolidated Financial Statements

TRUE NATURE HOLDING, INC.

Unaudited Consolidated Statements of Cash Flows

	Three Months Ended
	March 31,			March 31,
	2016			2015
Cash Flows from Operating Activities:
Net Loss	$	(838,587	)	$	(622,470	)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss from discontinued operations		—			622,470
Stock-based compensation		12,284			—
Accretion for debt discounts, warrants and issuance costs		2,325			—
Shares issued for board of director compensation		290,000			—
Shares issued for consulting services		297,500			—
Changes in operating assets and liabilities:
Prepaid expenses		(11,348	)		—
Prepaid expenses – related party		12,750			—
Accounts payable		56,738			—
Accrued interest and other liabilities		54,034			—
Net Cash Used in Operating Activities	$	(124,304	)	$	—

Cash Flows from Financing Activities:
Proceeds from issuance of convertible note payable		60,000			—
Sale of common stock, net of issuance costs		54,000			—
Net Cash Provided by Financing Activities	$	114,000		$	—
Discontinued Operations:
Operating activities		—			(154,051	)
Investing activities		—			(47,681	)
Financing activities		—			204,137
Net Increase in Cash and Cash Equivalents for Discontinued Operations		—			2,405
Net Decrease in Cash and Cash Equivalents for Continuing Operations		(10,304	)		—
Cash, Beginning of Period		28,185			14,119
Cash, End of Period	$	17,881		$	16,524

Non-cash Financing Transactions:
Discount cost related to issuance of convertible note payable	$	32,577		$	202,916

The accompanying notes are an integral part of the Consolidated Financial Statements.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

Note 1 – Description of Business

True Nature Holding, Inc. (the “Company”), previously known as Trunity Holdings, Inc., became a publicly-traded company through a reverse merger with Brain Tree International, Inc., a Utah corporation (“BTI”). Trunity Holdings, Inc. was the parent company of the prior educational business, named Trunity, Inc., which was formed on July 28, 2009 through the acquisition of certain intellectual property by its three founders. On December 31, 2015, the Company completed the restructuring and spin-out of the educational business.

True Nature Holding, Inc. intends to acquire a series of businesses which specialize in compounding pharmacy activities, largely direct to consumers, doctors and veterinary professionals.

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation - The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information, with the instructions to Form 10-Q and with Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required for complete financial statements. In the opinion of management, these consolidated financial statements contain all normal recurring adjustments considered necessary for a fair presentation of the Company’s financial position at March 31, 2016, the results of operations for the three months ended March 31, 2016 and 2015, and cash flows for the three months ended March 31, 2016 and 2015. The results for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the full year. These statements should be read in conjunction with the Company’s audited consolidated financial statements and management’s discussion and analysis included in the Company’s annual report on Form 10-K for the year ended December 31, 2015. In addition, refer to Note 4 regarding the spin-out of the educational business and related discontinued operations classification pertaining to the fiscal 2015 period. Common stock share and per share amounts in these financial statements have been retroactively adjusted for the effects of a 1 for 101 reverse stock split that occurred in January 2016.

Use of Estimates - The preparation of these financial statements requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and related notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment.

Per Share Data - Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the year. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents (if dilutive) related to warrants, options and convertible instruments.

The Company has excluded all common equivalent shares outstanding for warrants, options and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of March 31, 2016, the Company had 78,462 warrants, 67,879 options, 7,105 potential shares which may be issued resulting from the provisions of convertible notes, respectively. As of March 31, 2015, the Company had 166,415 warrants, 68,473 options, 223,223 potential shares which may be issued resulting from the provisions of convertible notes, respectively.

Recently Issued Accounting Standards-In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. This updated guidance supersedes the current revenue recognition guidance, including industry-specific guidance. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The updated guidance is effective for interim and annual periods beginning after December 15, 2016, and early adoption is not permitted. In July 2015, the FASB decided to delay the effective date of ASU 2014-09 until December 15, 2017. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The Company is currently evaluating which transition method it will adopt and the expected impact of the updated guidance, but does not believe the adoption of the updated guidance will have a significant impact on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases, which requires the lease rights and obligations arising from lease contracts, including existing and new arrangements, to be recognized as assets and liabilities on the balance sheet. ASU 2016-02 is effective for reporting periods beginning after December 15, 2018 with early adoption permitted. While the Company is still evaluating ASU 2016-02, the Company expects the adoption of ASU 2016-02 to have a material effect on the Company’s consolidated balance sheets and results of operations due to the recognition of the lease rights and obligations as assets and liabilities. The Company does not expect ASU 2016-02 to have a material effect on the Company’s cash flows.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

In January 2016, the FASB issued ASU 2016-01, Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities, which addresses certain aspects of recognition, measurement, presentation and disclosure of financial statements. This guidance will be effective in the first quarter of fiscal year 2019 and early adoption is not permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which addresses certain aspects of accounting for share-based payment award transactions. This guidance will be effective in the first quarter of fiscal year 2017 and early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.

Note 3 – Financial Condition and Going Concern

As of March 31, 2016, the Company had cash on hand of $17,881 and current liabilities of $705,243 and has incurred a loss from operations. True Nature Holding’s planned principal operations pertain to the business development and acquisition of pharmaceutical compounding companies. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan.

As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern. The Company’s continuance is dependent on raising capital and generating revenues sufficient to sustain operations. The Company believes that the necessary capital will be raised and has entered into discussions to do so with certain individuals and companies. However, as of the date of these consolidated financial statements, no formal agreement exists.

The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

Note 4 – Spin-Out and Discontinued Operations

On December 31, 2015, the Company completed the restructuring and spin-out of software educational business, resulting in True Nature Holding, Inc. becoming purely focused on acquiring a series of businesses which specialize in compounding pharmacy activities, largely direct to consumers, doctors and veterinary professionals. The results of the operations associated with the spin-out company and Trunity Holdings, Inc., qualifies as discontinued operations as of and for the three month period ended March 31, 2015.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

The results of operations associated with discontinued operations were as follows:

	March 31,
	2015
Net Sales	$	118,679
Cost of sales		62,128
Gross Profit		56,551

Operating Expenses:
Research and development		194,699
Selling, general and administrative		252,266
Total operating expenses		446,965

Operating Loss from Discontinued Operations		(390,414	)

Other Expense:
Interest expense, net		(232,056	)

Net Loss from Discontinued Operations	$	(622,470	)
Other Comprehensive Loss Net of Tax:
Foreign currency translation adjustments		(1,275	)
Comprehensive Loss from Discontinued Operations	$	(623,745	)

Our educational business was fully disposed of in December 2015. As a result, there were no assets or liabilities of discontinued operations as of 12/31/2015 or 3/31/2016.

Note 5 – Related Party Transactions

The Company’s Chairman of the Board, CEO and CFO, Stephen Keaveney has a consulting agreement in the amount of $10,000 per month for professional fees and was paid $16,000 during the three months ending March 31, 2016. On January 25, 2016 board member William L. Ross and Jeffrey Cosman were awarded each 100,000 of shares in Trunity, Inc. in exchange for their services as board members. In addition, a shareholder of the Company has a consulting agreement in the amount of $10,000 per month for professional fees and was paid $17,250 during the three months ended March 31, 2016. $4,250 and $17,000 has been classified as a prepaid asset as of March 31, 2016 and December 31, 2015, respectively, in the consolidated balance sheets related to the prepayment of consulting fees.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

Note 6 – Debt

Convertible Promissory Note

On March 18, 2016, the Company issued a 12% Convertible Promissory Note (the “Convertible Note”) in the principal amount of $60,000 to the Lender. Pursuant to the terms of the Convertible Note, on the date thereof, the Company issued the Convertible Note to the Lender and, as consideration therefor, the Lender paid the Company in cash the full principal amount of the Convertible Note. Upon issuance the lender was awarded 15,000 restricted common shares as an origination fee which have certain registration rights.

Pursuant to the terms of the Convertible Note, the Company is obligated to pay monthly installments of not less than $1,000 the first of each month commencing the month following the execution of this note until its full maturity on September 16, 2016 at which time the Company is obligated to repay the full principal amount of the Convertible Note. The Convertible Note is convertible by the holder at any time into shares of the Company’s common stock at an effective conversion price of $1.00 and throughout the duration of this Convertible Note the holder has the right to participate in any and other financing the Company may engage in with the same terms and option as all other investors. The Company allocated the face value of the Convertible Note to the shares and the note based on relative fair values, and the amount allocated to the shares of $16,364 was recorded as a discount against the note, with an offsetting entry to additional paid-in capital. The beneficial conversion feature of $16,364 was recorded as a debt discount with an offsetting entry to additional paid-in capital decreasing the note payable and increasing debt discount. The debt discount is being amortized to interest expense over the term of the debt. As of March 31, 2016, the carrying value of this Convertible Note was $29,598 and accrued interest expense of $260. For the three months ended March 31, 2016, debt discount amortization related to the Convertible Note was $2,325 and interest expense of $260.

August 2014 Convertible Debentures (Series C)

In fiscal 2015, all debentures issued by Trunity Holdings, Inc. to fund the former educational business were eligible to participate in a debt conversion; however, one debenture holder that was issued a Series C Convertible Debenture (the “Series C Debenture”) in August 2014 with an aggregate face value of $100,000 in exchange for the cancellation of Series B Convertible Debentures with a carrying value of $110,833 did not convert. The Series C Debenture accrues interest at an annual rate of 10%, matured on October 31, 2015, and is convertible into the Company’s common stock at a conversion rate of $20.20 per share. The holders of the Series C Debenture also received warrants to acquire 4,950 shares post-split of common stock for an exercise price of $20.20 per share, exercisable over five years. The former educational business in fiscal 2014 allocated the face value of the Series C Debenture to the warrants and the debentures based on its relative fair values, and allocated to the warrants, which was recorded as a discount against the Series C Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed in fiscal 2014 upon execution of the new debentures. As of March 31, 2016, the carrying value of this Series C Debenture was $110,833 and accrued interest expense of $16,625. For the three months ended March 31, 2016, interest expense related to the Debenture was $3,288.

November 2014 Convertible Debentures (Series D)

In fiscal 2015, all debentures issued by Trunity Holdings, Inc. to fund the former educational business were eligible to participate in a debt conversion however one debenture holder that was issued a Series D Convertible Debenture (the “Series D Debenture”) in November 2014 with an aggregate face value of $10,000 in exchange for the cancellation of Series B Convertible Debenture with a carrying value of $11,334 that did not participate in the debt conversion restructuring. The Series D Debenture accrues interest at an annual rate of 12%, matured on October 31, 2015, and is convertible into the Company’s common stock at a conversion rate of $16.67 per share. The holders of the Series D Debenture also received warrants to acquire 495 shares post-split of common stock for an exercise price of $20.20 per share, exercisable over five years. The former educational business in fiscal 2014 allocated the face value of the Series D Debenture to the warrants and the debentures based on their relative fair values, and allocated to the warrants, which was recorded as a discount against the Series D Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed in fiscal 2014 upon execution of the new debentures. As of March 31, 2016, the carrying value of the Series D Debenture was $11,334 and accrued interest expense of $1,927. For the three months ended March 31, 2016, interest expense related to the Debenture was $346.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

Note 7 – Stockholders’ Deficit

Sale of Common Stock – During the quarter ended March 31, 2016, the Company raised gross proceeds of $60,000 through the sale of 120,000 shares of common stock to accredited investors in private placement transactions at a price of $0.50 per share. The Company incurred $6,000 of securities issuance costs representing commissions paid to broker-dealers who assisted with these transactions.

Shares for Consulting Services and Board Members – During the quarter ended March 31, 2016, in connection with services rendered, the Company issued 300,000 restricted shares of the Company’s common stock at a value of $1.45 and $0.90 per share in exchange for financial consulting services conducted on behalf of the Company. In addition, in connection with services rendered for board members, the Company issued 200,000 restricted shares of the Company’s common stock at a value of $1.45 per share in exchange for their services conducted on behalf of the Company.

Shares issued for convertible note payable – As discussed in Note 6, during the quarter ended March 31, 2016, in connection with conversion of a six-month convertible promissory note, the Company issued 15,000 shares of the Company’s common stock with a fair value of $16,363 that was allocated based on the relative fair value of the note and associated shares.

Debt beneficial conversion feature for convertible note payable – During the quarter ended March 31, 2016, the Company raised gross proceeds of $60,000 pursuant to a Convertible Note Payable (“Note”) that allocated the face value of the Note to the shares and debt based on their relative fair values and, resulted in the recording of beneficial conversion features totaling $16,364 as a discount against the Notes, with an offsetting entry to additional paid-in capital. The discount is being amortized into interest expense over the term of the Note.

Note 8 – Stock-Based Compensation

The Company has two Employee, Director and Consultant Stock Option Plans that were not terminated as a result of the fiscal 2015 restructuring of the Company and spin-out and have continued as part of the operations as detailed below.

In fiscal 2015, the option pool pertaining to the 2009 Employee, Director and Consultant Stock Option Plan (the “2009 Plan”) was adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan, resulting in an authorized option pool of 18,152. Stock options typically vest over a three-year period and have a life of ten years from the date granted. As of March 31, 2016 there were 3,610 shares available for future awards under this plan.

In fiscal 2015, the option pool pertaining to the 2012 Employee, Director and Consultant Stock Option Plan (the “2012 Plan”) was adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan, resulting in an authorized options pool of 74,257. Stock options typically vest over a three year period and have a life of ten years from the date granted. As of March 31, 2016, there were 45,673 shares available for future awards under this plan.

In addition, there are approximately 24,753 in options outstanding that were issued to a former CEO of the Company in fiscal 2014. These options issued are outside of the 2009 and 2012 Plans.

During the quarter ended March 31, 2016, the Company did not grant options to acquire shares of common stock to employees, directors or consultants.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

For all previous grants the fair value of options is estimated using the Black-Scholes option pricing model. The expected term of options granted is based on the simplified method in accordance with Securities and Exchange Commission Staff Accounting Bulletin 107, and represents the period of time that options granted are expected to be outstanding. The Company makes assumptions with respect to expected stock price volatility based on the average historical volatility of peers with similar attributes. In addition, the Company determines the risk free rate by selecting the U.S. Treasury with maturities similar to the expected terms of grants, quoted on an investment basis in effect at the time of grant for that business day.

As of March 31, 2016, there was approximately $780 of total unrecognized stock compensation expense, related to unvested stock options under the Plans. This expense is expected to be recognized over the remaining weighted average vesting periods of the outstanding options of less than one year. The Company recorded $12,284 in stock compensation expense to continuing operations within selling, general and administrative expenses on the consolidated statements of operations and comprehensive loss pertaining to the vesting of options in fiscal 2016.

A summary of options issued, exercised and cancelled are as follows:

	Shares		Weighted- Average Exercise Price ($)		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value ($)
Outstanding at December 31, 2015		67,879	$	21.40		7.17		—
Granted		—		—		—		—
Cancelled		—		—		—		—

Outstanding at March 31, 2016		67,879	$	21.40		6.92		—

Exercisable at March 31, 2016		66,635	$	21.78		6.82		—

Note 9 – Warrants to Purchase Common Stock

Subsequent to the restructuring of the Company and the spin-out, the Company had warrants to purchase common stock outstanding that were not terminated and have continued as part of the operations as detailed below. The warrants were adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan as authorized. No warrants were issued during the first quarter ended March 31, 2016. All warrants outstanding as of March 31, 2016 are scheduled to expire at various dates through 2019. A summary of warrants issued, exercised and expired are as follows:

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

	Shares		Weighted- Average Exercise Price ($)		Weighted-Average Remaining Contractual Term
Outstanding at December 31, 2015		78,462	$	29.55		3.43
Granted		—		—		—
Expired		2,475		50.50		—

Outstanding at March 31, 2016		75,987	$	30.51		3.29

Exercisable at March 31, 2016		75,987	$	30.51		3.29

Note 10 – Commitments and Contingencies

Legal

National Council for Science and the Environment, Inc. v. Trunity Holdings, Inc., Case No.. 2015 CA 009726 B, Superior Court for the District of Columbia, Civil Division.

This action was filed on December 16, 2015 by the National Council for Science and the Environment, Inc. (“NCSE”) in the state court in the District of Columbia against Trunity Holdings, Inc. (“Trunity”) and alleges claims for Breach of Contract. Acknowledgement of Indebtedness and Settlement Agreement and Quantum Meruit arising out of an agreement entered into between NCSE and Trunity in 2014. The Complaint seeks damages in the amount of $177,270, inclusive of attorney’s fees, costs and accrued interest, continuing interest in the amount of 12% per annum and attorney’s fees and costs of collection relating to the case. The Company in its answer on January 27, 2016, denied the material allegations made by NCSE, asserted a number of affirmative defenses and filed a counterclaim alleging claims for fraud, negligent misrepresentation, breach of fiduciary duty, breach of contract and unjust enrichment. In its counterclaim, the Company will seek actual and compensatory damages against NCSE that it believes exceed the amount sought by NCSE on its claims, pre-judgment interest, punitive damages and all costs and expenses, including attorney’s fees, incurred by the Company in bringing its claims against NCSE.

On February 19, 2016, NCSE filed a motion to dismiss the counterclaim, and the Company has filed its brief in the opposition to that motion. A hearing is scheduled in second quarter 2016 on the motion. No discovery has been conducted by the parties yet, and no trial date has been set by the court. We have recorded a liability as of March 31, 2016 based on our best estimate of the probable exposure pertaining to the claim.

Note 11 – Subsequent Events

On April 4, 2016 the Company entered into a non-binding letter of intent to acquire a compounding pharmacy in Holly Springs, Georgia, a suburb of Atlanta. The agreement calls for purchase consideration of approximately $450,000. Payment will be split between the issuance of common stock, a convertible note that may convert into stock at a price not less than $2 per share. The final allocation of each of these will be determined prior to closing, which is expected to occur in June 2016. The letter of intent is not a definitive agreement, and the Company anticipates that the definitive agreement will contain customary conditions to closing.

On April 11, 2016 the Board of Directors elected Mr. James Driscoll, age 54, to the Board of Directors. Mr. Driscoll is currently CEO of Channel Terminals, LLC, a crude oil liquids terminals and refinery based in Houston, TX. Mr. Driscoll is also a member of the Board of Directors at Double Zero Recycling LLC as well as an Advisory Board Member at HealPros LLC, a diabetic retinal imaging business, and Funding University LLC, an early stage online peer to peer lending business targeted on secondary education. Previously he was President of Method Holdings, LLC, from 2011 until late 2013. Between 2006 and 2011 Mr. Driscoll was a Senior Partner with private equity firm 1848 Capital Partners LLC. From 2009 to 2010 he was COO and Executive Vice President of CareDynamix LLC, a healthcare business focused on provision of onsite vaccination services around the US. In addition, Mr. Driscoll, has over 14 years of experience at various senior positions in the power generation and transportation industries in varied locations around the world. He began his professional career as a trader in New York City. He has an MBA from Harvard University (1991) and a BA in English Literature from Bowdoin College (1984). Mr. Driscoll will receive 100,000 shares of restricted common stock as compensation for his term on the Board, consistent with all prior appointments by the Company.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

On April 11, 2016, Dr. William Ross, age 70, advised the Company that he desired to resign from the Board of Directors, as he intends to retire from all business activities. There were no disagreements, or conflicts with the Board and Dr. Ross.

On April 29, 2016, subject to approval by the Georgia Board of Pharmacy, the Company entered into definitive documents to acquire P3 Compounding of Georgia, LLC,following the letter of intent dated March 29, 2016. The total consideration for the transaction is $1,000,000. The transaction includes the acquisition of certain special formulations as “Intellectual Properties”.

The consideration paid was comprised of three (3) components:

1) the business interests were acquired in consideration of a) $425,000 of convertible notes with a conversion price of $1.25 per share and interest of 6% and b) a short term note in the amount of $75,000, non-interest bearing, with a maturity of June 16, 2016;

2) the specialized formulations of the business, which will be included in the Company’s library of Intellectual Properties, were acquired in consideration a) $425,000 of convertible notes with a conversion price of $1.25 per share and interest of 6% and b) a short term note in the amount of $75,000, non-interest bearing, with a maturity of June 16, 2016;

3) Mr. Casey Gaetano, employed under a 3 year employment contract as VP of Corporate Development, at an annual salary of $125,000, plus normal benefits commensurate with other executives in the Company of equal stature. He will also receive 125,000 shares of restricted stock in the amount.

The notes issued in conjunction with the purchase and the intellectual properties may be converted into restricted common stock at a rate of $1.25 per share. The purchase includes all payables, receivables, cash on hand, inventory and all assets used in the operation of the business.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and the related notes thereto contained in Part I, Item 1 of this Quarterly Report on Form 10-Q (this “Quarterly Report”). Our consolidated financial statements have been prepared and, unless otherwise stated, the information derived therefrom as presented in this discussion and analysis is presented, in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

The information contained in this Quarterly Report is not a complete description of our business or the risks associated with an investment in our common stock. We urge you to carefully review and consider the various disclosures made by us in this Quarterly Report and in our other reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and subsequent reports on Form 8-K, which discuss our business in greater detail. Unless the context indicates otherwise, the “Company”, “we”, “us”, and “our” in this Item 2 and elsewhere in this Quarterly Report refer to True Nature Holdings, Inc., a Delaware corporation, and its consolidated subsidiaries.

In addition to historical information, the following discussion contains forward-looking statements regarding future events and our future performance. In some cases, you can identify forward-looking statements by terminology such as “will”, “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “forecasts”, “potential” or “continue” or the negative of these terms or other comparable terminology. All statements made in this Quarterly Report other than statements of historical fact are forward-looking statements. These forward-looking statements involve risks and uncertainties and reflect only our current views, expectations and assumptions with respect to future events and our future performance. If risks or uncertainties materialize or assumptions prove incorrect, actual results or events could differ materially from those expressed or implied by such forward-looking statements. Risks that could cause actual results to differ from those expressed or implied by the forward-looking statements we make include, among others, risks related to: our ability to successfully implement our business plan, develop and commercialize our proprietary formulations in a timely manner or at all, identify and acquire additional proprietary formulations, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally; our limited operating history; and the other risks and uncertainties described under the heading “Risk Factors” in Part II, Item 1A of this Quarterly Report. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made and, except as required by law, we undertake no obligation to revise or publicly update any forward-looking statement for any reason.

Overview

We are an early stage company that intends to acquire a series of businesses which specialize in compounding pharmacy activities, largely direct to consumers, and to doctors and veterinary professionals.

Description of Pharmaceutical Compounding

The vast majority of medications are mass-produced by pharmaceutical drug companies. They aim to treat a specific medical condition for a large segment of people. Problems can arise when a patient has a medical condition that can’t be treated by one of these mass-produced products. Pharmaceutical compounding (done in compounding pharmacies) is the creation of a particular pharmaceutical product prescribed by doctors to fit the unique needs of a patient that can’t be met by commercially available drugs. To do this, compounding pharmacists combine or process appropriate ingredients using various tools. This may be done for medically necessary reasons, such as to change the form of the medication from a solid pill to a liquid, to avoid a non-essential ingredient that the patient is allergic to, or to obtain the exact dose(s) needed or deemed best of particular active pharmaceutical ingredient(s). It may also be done for more optional reasons, such as adding flavors to a medication or otherwise altering taste or texture. Examples of compounded formulations include medications with alternative dosage strengths or unique dosage forms, such as topical creams or gels, suspensions or solutions with more tolerable drug delivery vehicles. Compounding pharmacies (and pharmacists) adhere to standards and regulations set by the U.S. Pharmacopeia, National Association of Boards and State Boards of Pharmacy for quality assurance and accuracy. The compounding pharmacy business has the potential to provide high margins, and allow the pharmacy to specialize is certain solutions for specific maladies, so it can target specific markets efficiently.

We intend to focus on the acquisition of compounders who have a) a large client base in the veterinary area, b) a strong set of proprietary compounding solutions, versus non-proprietary “over-the-counter” (OTC) medicine sales, and c) where the combination of incremental operations will allow cross selling of a growing line of proprietary compounds into the respective markets of each new market participant acquired.

We expect economies of scale from the consolidation of:

●	Materials procurement;
●	Compounding activities combined into larger, more efficient and higher quality facilities;
●	Expanded marketing nationwide with an emphasis on densely populated urban areas where an expanded product line may increase the profitability of each individual branch, when compared to pre-acquisition sales, and;
●	Consolidated administration and personnel functions.

Off-Balance Sheet Arrangements

Since our inception, except for standard operating leases, we have not engaged in any off-balance sheet arrangements, including the use of structured finance, special purpose entities or variable interest entities. We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Critical Accounting Policies

In the first quarter of 2016, there were no significant changes to our critical accounting policies and estimates from those disclosed in the section “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2015 Form 10-K.

Recently Issued and Adopted Accounting Pronouncements

See Note 2 to our consolidated financial statements included in this Quarterly Report.

Results of Operations

The following period-to-period comparisons of our financial results are not necessarily indicative of results for the current period or any future period. In particular, our pharmacy operations activities will commence in the second quarter of 2016 and we have spun-out the prior year educational business which is presented as discontinued operations in the consolidated financial statements. This change in the nature of our operations will have and is expected to continue to have a significant impact on our financial results. As a result, our results of operations in the periods after commencement of our pharmacy operations will include aggregate revenue and expense amounts and the apportionment of expenses among categories, have changed and are expected to continue to change as we further develop these operations. Further, as a result of our acquisitions of our compounding pharmacies, and any additional pharmacy acquisitions or other such transactions we may pursue, we may experience large expenditures specific to the transactions that are not incident to our operations.

For the Three Months ended March 31, 2016 and 2015

There are no continuing operating sales and related cost of sales for the three months ended March 31, 2016 as the Company is implementing its business plan to acquire and develop compounding pharmacies. We plan to report revenue during the second quarter of 2016 if we close certain acquisitions of our compounding pharmacies. As a result of pharmacy acquisitions or other such transactions we may pursue, we may experience large expenditures specific to these transactions.

Our total operating expenses for the first three months ended March 31, 2016 pertaining to continuing operations were $832,369 that were comprised primarily of expenses of $587,500 pertaining to shares issued for board and consulting services (noncash), $97,973 of management and accounting fees and $75,259 of professional fees related to SEC filings and other legal matters.

There is $6,218 of interest expense for the three months ended March 31, 2016 pertaining to continuing operations and relates to interest incurred for outstanding debentures that were not converted resulting from the spin-out and the newly issued convertible promissory note.

There was a net loss for continuing operations of $838,587 for the three months ended March 31, 2016 resulting from the aforementioned operating expenses.

A comparison has not been provided for three months ended March 31, 2015 as the financial results for three months ended March 31, 2015 are reported as discontinued operations as discolsed in Note 4 to the consolidated financial statements.

Liquidity and Capital Resources

We have financed our operations through the sale of equity securities. As of March 31, 2016, we had a working capital deficit of $671,764. Our working capital deficit is attributable to the fact that the Company began implementing its business plan of acquiring pharmaceutical compounding businesses at the end of fiscal 2015. No planned revenue activity will be reported until the second quarter of 2016.

Net cash used in operating activities from continuing operations was $124,304 for the three months ended March 31, 2016 which primarily reflects our business development efforts that pertaining to acquiring a series of businesses which specialize in compounding pharmacy activities, largely direct to consumers, doctors and veterinary professionals.

Net cash provided by financing activities for the three months ended March 31, 2016 was approximately $114,000 which represents the cash that was received from sale of common stock and issuance of a convertible note payable.

A comparison has not been provided for three months ended March 31, 2015 as the financial results for three months ended March 31, 2015 are reported as discontinued operations as disclosed in Note 4 to the consolidated financial statements.

Specific details related to our financing activities are as follows:

2016 Private Placements

During the quarter ended March 31, 2016, we raised gross proceeds of $60,000 through the sale of 120,000 shares of common stock to accredited investors in private placement transactions at a price of $0.50 per share. We incurred $6,000 of securities issuance costs representing commissions paid to broker-dealers who assisted with these transactions.

On March 18, 2016, we issued a 12% Convertible Promissory Note (the “Convertible Note”) in the principal amount of $60,000 to the Lender. Pursuant to the terms of the Convertible Note, on the date thereof, we issued the Convertible Note to the Lender and, as consideration therefor, the Lender paid us in cash the full principal amount of the Convertible Note. Upon issuance the lender was awarded 15,000 restricted common shares as an origination fee which will have piggy back registration rights.

Plan of Operations

We are entering the Compounding Pharmacy Industry via a roll-up of existing compounding pharmacies consolidating fragmented market. The key elements of our strategy include:

	■	we intend to grow regionally, building regional distribution centers, expand sales and marketing with eventually with a national presence;
	■	we intend to acquire multiple libraries of compounding formulations in the process, recognizing that:
		some are tailored for local needs;
	■	some will have regional markets with expanded marketing;
	■	some can become nationally accepted, and further “productized” solutions;
	■	in all cases, we intend to drive the costs down when compared to alternatives from “big pharma”.

The human market and the vet market are both large and growing, share many of the same solutions, and are in need of lower cost solutions. We will focus on a balance between legitimate insurance related revenue streams and cash pay business. We believe the pharmacy industry, and especially compounding pharmacy, can easily be described as having multiple “flavors”. We believe the markets for both people and pets are both underserved:

	■	Some sell basic OTC medications and provide “delivery only”, and most users rely on insurance reimbursement for payment;
	■	Some are “value added resellers”, using OTC recognized medications, then repackaging, or using combinations, to personalize the product for the client. While vet based is a cash business, the human side is largely insurance reliant;
	■	Some are like “OEM manufacturers”, like a generic drug maker, starting with basic, non-productized materials, and creating both standard and fully customized “novel” formulations for specific maladies and needs. These are more often cash clients, and this approach is well accepted in the pet area, and becoming more accepted for people as alternatives to OTC, and for cash buyers seeking lower cost;
	■	We believe a mix of these can serve the need to drive costs down, and allow innovative approaches to improve patient results.

Recent Developments

On April 4, 2016 the Company entered into a non-binding letter of intent to acquire a compounding company in Holly Springs, Georgia, a suburb of Atlanta. The agreement calls for purchase consideration of approximately $450,000. Payment will be split between the issuance of common stock, a convertible note that may convert into stock at a price not less than $2 per share. The final allocation of each of these will be determined prior to closing, which is expected to occur in June 2016. The letter of intent is not a definitive agreement, and the Company anticipates that the definitive agreement will contain customary conditions to closing.

On April 29, 2016, subject to approval by the Georgia Board of Pharmacy, the Company entered into definitive documents to acquire P3 Compounding of Georgia, LLC., following the letter of intent dated March 29, 2016. The total consideration for the transaction is $1,000,000. The transaction includes the acquisition of certain special formulations as “Intellectual Properties”. It also includes an employment contract for Mr. Gaetano for three (3) years, including a salary of $125,000 per year and 125,000 of restricted stock.

The consideration paid was comprised of three (3) components:

1) the business interests were acquired in consideration of a) $425,000 of convertible notes with a conversion price of $1.25 per share and cash pay interest of 6% and b) a short term note in the amount of $75,000, accruing 0%, with a maturity of June 16, 2016;

2) the specialized formulations of the business, which will be included in the Company’s library of Intellectual Properties, were acquired in consideration a) $425,000 of convertible notes with a conversion price of $1.25 per share and cash pay interest of 6% and b) a short term note in the amount of $75,000, accruing 0%, with a maturity of June 16, 2016;

3) the founder of Integrity, Mr. Casey Gaetano, was employed as VP of Corporate Development, at an annual salary of $125,000, plus normal benefits commensurate with other executives in the Company of equal stature. He will also receive 125,000 shares of restricted stock in the amount.

During the first quarter of 2016, the Company raised gross proceeds of $60,000 through the sale of 120,000 shares of Common Stock to accredited investors in private placement transactions at a price of $0.50 per share. There were no issuance and commission costs incurred pertaining to the raise.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

This Item is not required for a Smaller Reporting Company.

ITEM 4. CONTROLS AND PROCEDURES.

As of the end of the period covered by this report (the “Evaluation Date”), we carried out an evaluation regarding the fiscal quarter ended March 31, 2016, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer who is also serving as our Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon this evaluation, our management concluded that, as of the Evaluation Date, our disclosure controls and procedures were not effective to provide reasonable assurance that information required to be disclosed in the reports that are filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified by the Securities and Exchange Commission’s rules and forms and that our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that the Company’s disclosure controls and procedures will detect or uncover every situation involving the failure of persons within the Company to disclose material information otherwise required to be set forth in the Company’s periodic reports.

The Company’s management is also responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. As of the Evaluation Date, no changes in the Company’s internal control over financial reporting occurred that have materially affected or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Our Annual Report on Form 10-K contains information regarding a material weakness in our internal control over financial reporting as of December 31, 2015 due to an inadequate segregation of duties resulting from our limited number of employees whom duties can be allocated.

During the first quarter of 2016, there were no changes that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 1. Legal Proceedings

In December 2015 we were named as Defendant in a suit from National Council for Science in the Environment (NCSE) seeking to collect $170,000 related to a services and consulting relationship dating back to 2009, a part of the legacy educational business, and not related to our ongoing pharmacy activities. We have filed a response and counterclaims including fraud claim. We believe our counterclaim for damages will far exceed the amounts they sought to recover. We intend to vigorously defend their claims. We have recorded a liability as of March 31, 2016 based on our best estimate of the probably exposure pertaining to the claim.

ITEM 1A. Risk Factors

We believe there are no changes that constitute material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on May 2nd, 2016.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

2016 Private Placements

During the quarter ended March 31, 2016, the Company raised gross proceeds of $60,000 through the sale of 120,000 shares of common stock to accredited investors in private placement transactions at a price of $0.50 per share. The Company incurred $6,000 of securities issuance costs representing commissions paid to broker-dealers who assisted with these transactions.

2015 Private Placements

The Company acquired 100% of the membership interests of Newco4pharmacy, LLC, a business aimed at creating a nationwide network of compounding pharmacies. The consideration paid was the issuance of a newly created Series X Preferred stock which was exchanged on December 31, 2015 for 10,000,000 shares of our common stock. The Company obtained approximately $106,900 in cash from Newco4pharmacy. Funds received resulted from a Newco4pharmacy membership interest sale prior to the transaction. As a result of this transaction the Company issued Founders shares of 3,488,900 to the CEO and Founder, Stephen Keaveney and 3,988,900 to individuals and entities that were instrumental in the formation of the N4P business. The Company also issued 455,000 shares to broker-dealers and 1,353,200 to other individuals for services performed in connection with the formation of the company.

August 2014 Convertible Debentures (Series C)

As part of the restructuring all debentures issued by Trunity Holdings, Inc., to fund the former educational business were eligible to participate in a debt conversion however one debenture holder that was issued a Series C Convertible Debenture (the “Series C Debenture”) in August 2014 with an aggregate face value of $100,000 in exchange for the cancellation of Series B Convertible Debentures with a carrying value of $110,833 did not convert. The Series C Debenture accrues interest at an annual rate of 10%, matured November 2015, and is convertible into the Company’s common stock at a conversion rate of $20.20 per share. The holders of the Series C Debenture also received warrants to acquire 4,950 shares post-split of common stock for an exercise price of $20.20 per share, exercisable over five years. The former educational business allocated the face value of the Series C Debenture to the warrants and the debentures based on its relative fair values, and allocated to the warrants, which was recorded as a discount against the Series C Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed upon execution of the new debentures. As of March, 2016, the carrying value of this Series C Debenture was $110,833 and accrued interest expense of $16,625.

November 2014 Convertible Debentures (Series D)

As part of the restructuring all debentures issued by Trunity Holdings, Inc., to fund the former educational business were eligible to participate in a debt conversion however one debenture holder that was issued a Series D Convertible Debenture (the “Series D Debenture”) in November 2014 with an aggregate face value of $10,000 in exchange for the cancellation of Series B Convertible Debenture with a carrying value of $11,333 that did not participate in the debt conversion restructuring. The Series D Debenture accrues interest at an annual rate of 12%, matured November 2015, and is convertible into the Company’s common stock at a conversion rate of $16.67 per share. The holders of the Series D Debenture also received warrants to acquire 495 shares post-split of common stock for an exercise price of $20.20 per share, exercisable over five years. The former educational business allocated the face value of the Series D Debenture to the warrants and the debentures based on their relative fair values, and allocated to the warrants, which was recorded as a discount against the Series D Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed upon execution of the new debentures. As of March 31, 2016, the carrying value of the Series D Debenture was $11,333 and accrued interest expense of $1,927.

All of the shares issued in the transactions described above were issued in private placement transactions and were exempt from registration under Section 4(2) of the Securities Act of 1933, as amended, as sales of securities not involving a public offering.

ITEM 3. Defaults upon Senior Securities

None.

ITEM 4. Mine Safety Disclosures.

This Item is not applicable to our company’s operations.

ITEM 5. Other Information

None.

PART IV

Exhibit Number		Description
3.1		Certificate of Incorporation of Trunity Holdings, Inc. dated as of January 18, 2012 (incorporated herein by reference to Exhibit 10.1 filed as part of the Company’s Form 8-K dated January 24, 2012 (Commission File No. 000-53601)).

3.2		Certificate of Ownership and Merger dated as of January 24, 2012, between Trunity Holdings, Inc. and Brain Tree International, Inc. (incorporated herein by reference to Exhibit 3.3 filed as part of the Company’s Form 10-K for the year ended December 31, 2012 (Commission File No. 000-53601)).

3.3		Certificate of Designation of Series X Preferred Stock of Trunity Holdings, Inc., dated as of December 9, 2015 (incorporated by reference to Exhibit 3.1 as part of the Company’s Form 8-K dated December 15, 2015 (Commission File No. 000-53601)

3.4		Certificate of Amendment to the Certificate of Incorporation of Trunity Holdings, Inc., dated as of December 24, 2015 (incorporated by reference to Exhibit 3.1(I) as part of the Company’s Form 8-K dated January 6, 2016 (Commission File No. 000-53601)

3.5		Bylaws of Trunity Holdings, Inc. (incorporated herein by reference to Exhibit 10.2 filed as part of the Company’s Form 8-K dated January 24, 2012 (Commission File No. 000-53601)).

10.1		Spin-off and Asset Transfer Agreement dated as of December 31, 2015, by and among Trunity Holdings, Inc., Trunity, Inc., a Delaware corporation, and Trunity, Inc., a Florida corporation.(incorporated by reference to Exhibit 10.1 as part of the Company’s Form 8-K dated January 6, 2016 (Commission File No. 000-53601))

10.2		Securities Exchange Agreement dated as of December 9, 2015 by and among Trunity Holdings, Inc. and the Members of Newco4Pharmacy, LLC (incorporated by reference to Exhibit 10.1 as part of the Company’s Form 8-K dated December 15, 2015 (Commission File No. 000-53601))

10.3		Consulting Agreement dated as of December 1, 2015 by and between Trunity Holdings, Inc. and Stephen Keaveney (incorporated by reference to Exhibit 10.2 as part of the Company’s Form 8-K dated December 15, 2015 (Commission File No. 000-53601))

10.4		Securities Purchase Agreement dated as of November 5, 2014 by and between Trunity Holdings, Inc. and Peak One Opportunity Fund, L.P. (incorporated by reference to Exhibit 10.15 as part of the Company’s Form 10-Q for the quarter ending September 30, 2014 (Commission File No. 000-53601))

10.5		Trunity Holdings, Inc. Non-Qualified Stock Option Agreement dated as of December 13, 2013 by and between Arol Buntzman and Trunity Holdings, Inc. (incorporated by reference to Exhibit 10.14 as part of the Company’s Form 10-K for the year ending December 31, 2013 (Commission File No. 000-53601))

10.6		Memorandum of Understanding Regarding Trunity Holdings, Inc. and PIC Partners dated as of June 5, 2013 by and between Pan-African Investment Company and Trunity Holdings, Inc. (incorporated by reference to Exhibit 10.13 as part of the Company’s Form 10-K for the year ending December 31, 2013 (Commission File No. 000-53601))

10.7		Indemnification Agreement dated May 30, 2013 between the Company and Pan African Investment Company (incorporated herein by reference to Exhibit 10.12 filed as part of the Company’s Form 10-K for the year ended December 31, 2013 (Commission File No. 000-53601)).

10.8		Voting Agreement dated June 5, 2013 by and among Trunity Holdings, Inc., Terry Anderton, RRM Ventures, LLC, Aureus Investments, LLC and Pan-African Investment Company, LLC (incorporated by reference to Exhibit C as part of the Company’s Schedule 13D dated July 25, 2013 (Commission File No. 000-53601))

10.9		Voting Agreement dated May 30, 2013 by and among Trunity Holdings, Inc., Terry Anderton, RRM Ventures, LLC, Aureus Investments, LLC and Pan-African Investment Company, LLC (incorporated by reference to Exhibit 10.11 as part of the Company’s Form 10-K for the year ending December 31, 2013 (Commission File No. 000-53601))

10.10		Investors Rights Agreement dated May 30, 2013 between the Company and Pan African Investment Company (incorporated herein by reference to Exhibit 10.10 filed as part of the Company’s Form 10-K for the year ended December 31, 2013 (Commission File No. 000-53601)).

10.11		Investors Rights Agreement dated June 5, 2013 between the Company and Pan African Investment Company (incorporated herein by reference to Exhibit D filed as part of the Company’s Schedule 13D dated July 25, 2013 (Commission File No. 000-53601)).

10.12		Subscription Agreement dated May 28, 2013 between the Company and Pan African Investment Company (incorporated herein by reference to Exhibit 10.9 filed as part of the Company’s Form 10-K for the year ended December 31, 2013 (Commission File No. 000-53601)).

10.13		Form of Indemnification Agreement between Trunity and its Directors (incorporated herein by reference to Exhibit 10.8 filed as part of the Company’s Form 10-K for the year ended December 31, 2012 (Commission File No. 000- 53601)).

10.14		License Agreement dated as of March 20, 2013, between Trunity and Educom Ltd. (incorporated herein by reference to Exhibit 10.7 filed as part of the Company’s Form 10-K for the year ended December 31, 2012 (Commission File No. 000-53601)).

10.15		Share Purchase Agreement dated as of March 20, 2013, between Trunity and InnSoluTech LLP (incorporated herein by reference to Exhibit 10.6 filed as part of the Company’s Form 10-K for the year ended December 31, 2012 (Commission File No. 000-53601)).

10.16		Investment Project Contract dated as of March 20, 2013, among Trunity, InnSoluTech LLP and Educom Ltd. (incorporated herein by reference to Exhibit 10.5 filed as part of the Company’s Form 10-K for the year ended December 31, 2012 (Commission File No. 000-53601)).

10.17		Trunity Holdings, Inc. 2012 Employee, Director and Consultant Stock Option Plan (incorporated herein by reference to Exhibit 10.4 filed as part of the Company’s Form 10-K for the year ended December 31, 2012 (Commission File No. 000-53601)).

10.18		Agreement and Plan of Merger, dated as of January 24, 2012 by and among Trunity Holdings, Inc., Trunity Acquisitions Corp. and Trunity, Inc. (incorporated herein by reference to Exhibit 10.5 filed as part of the Company’s Form 8-K dated January 24, 2012 (Commission File No. 000-53601)).

10.19		Stock Purchase Agreement between dated as of January 24, 2012 by and among George Norman, Donna Norman, Lane Clissold, Trunity Holdings, Inc. and Trunity, Inc. (incorporated herein by reference to Exhibit 10.3 filed as part of the Company’s Form 8-K dated January 24, 2012 (Commission File No. 000-53601)).

10.20		Agreement and Plan of Merger, dated as of January 24, 2012 by and among Brain Tree International, Inc. and Trunity Holdings, Inc. (incorporated herein by reference to Exhibit 10.4 filed as part of the Company’s Form 8-K dated January 24, 2012 (Commission File No. 000-53601)).

14		Code of Ethics (incorporated herein by reference to Exhibit 14 filed as part of the Company’s Form 10-K for the year ended December 31, 2012 (Commission File No. 000-53601)).

21		Subsidiaries of the Company (incorporated herein by reference to Exhibit 21 filed as part of the Company’s Form 10-K for the year ended December 31, 2012 (Commission File No. 000-53601)).

31.1 *		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2 *		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1 *		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS *		XBRL INSTANCE DOCUMENT

101.SCH *		XBRL TAXONOMY EXTENSION SCHEMA

101.CAL *		XBRL TAXONOMY EXTENSION CALCULATION LINKBASE

101.DEF *		XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

101.LAB *		XBRL TAXONOMY EXTENSION LABEL LINKBASE

101.PRE *		XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

* Filed herewith.

SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TRUE NATURE HOLDING, INC.

Dated: May 20, 2016	By:	/s/ Stephen Keaveney
		Stephen Keaveney Chief Executive Officer and Chief Financial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature and Title		Date

/s/ Stephen Keaveney		May 20, 2016
Stephen Keaveney
Chief Executive Officer, Chief Financial Officer, and Chairman of the Board

/s/ Jeff S. Cosman		May 20, 2016
Jeff S. Cosman
Director

/s/ James Driscoll		May 20, 2016
James Driscoll
Director

EX-31.1 2 ex31_1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Stephen Keaveney, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of True Nature Holding, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	TRUE NATURE HOLDING, INC.

Dated: May 20, 2016	By:	/s/ Stephen Keaveney
		Stephen Keaveney Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 ex31_2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Stephen Keaveney, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of True Nature Holding, Inc.;

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	TRUE NATURE HOLDING, INC.

Dated: May 20, 2016	By:	/s/ Stephen Keaveney
		Stephen Keaveney Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32 4 ex32.htm EXHIBIT 32

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of True Nature Holding, Inc. (the “Company”) for the quarter year ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stephen Keaveney, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

	TRUE NATURE HOLDING, INC.

Dated: May 20, 2016	By:	/s/ Stephen Keaveney
		Stephen Keaveney Chief Executive Officer and Chief Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. The foregoing certifications are accompanying the Company’s Form 10-Q solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.

EX-101.INS 5 tntyob-20160331.xml XBRL INSTANCE FILE 0000802257 2016-01-01 2016-03-31 0000802257 2016-05-19 0000802257 2015-12-31 0000802257 2016-03-31 0000802257 2015-01-01 2015-03-31 0000802257 us-gaap:CommonStockMember 2015-12-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000802257 us-gaap:RetainedEarningsMember 2015-12-31 0000802257 us-gaap:WarrantMember 2015-12-31 0000802257 us-gaap:WarrantMember 2016-01-01 2016-03-31 0000802257 tntyob:N2009EmployeeDirectorAndConsultantStockOptionPlanThe2009PlanMember 2015-12-31 0000802257 tntyob:N2012EmployeeDirectorAndConsultantStockOptionPlanThe2012PlanMember 2015-12-31 0000802257 tntyob:N2009EmployeeDirectorAndConsultantStockOptionPlanThe2009PlanMember 2015-01-01 2015-12-31 0000802257 tntyob:N2012EmployeeDirectorAndConsultantStockOptionPlanThe2012PlanMember 2015-01-01 2015-12-31 0000802257 tntyob:StephenKeaveneyMember 2016-01-01 2016-03-31 0000802257 tntyob:ShareholderMember 2016-01-01 2016-03-31 0000802257 tntyob:November2014ConvertibleDebenturesSeriesDMember 2015-01-01 2015-12-31 0000802257 tntyob:November2014ConvertibleDebenturesSeriesDMember 2015-12-31 0000802257 tntyob:August2014ConvertibleDebenturesSeriesCMember 2015-01-01 2015-12-31 0000802257 tntyob:August2014ConvertibleDebenturesSeriesCMember 2015-12-31 0000802257 tntyob:StephenKeaveneyMember 2016-03-31 0000802257 us-gaap:ChiefExecutiveOfficerMember 2014-12-31 0000802257 2015-12-01 2015-12-16 0000802257 us-gaap:SubsequentEventMember 2016-04-04 0000802257 tntyob:ShareholderMember 2016-03-31 0000802257 us-gaap:CommonStockMember 2016-01-01 2016-03-31 0000802257 us-gaap:CommonStockMember 2016-03-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-03-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0000802257 us-gaap:RetainedEarningsMember 2016-01-01 2016-03-31 0000802257 us-gaap:RetainedEarningsMember 2016-03-31 0000802257 2014-12-31 0000802257 2015-03-31 0000802257 2016-01-01 2016-01-31 0000802257 tntyob:N2009EmployeeDirectorAndConsultantStockOptionPlanThe2009PlanMember 2016-03-31 0000802257 tntyob:N2012EmployeeDirectorAndConsultantStockOptionPlanThe2012PlanMember 2016-03-31 0000802257 us-gaap:WarrantMember 2016-03-31 0000802257 tntyob:ConvertiblePromissoryNoteMember 2016-03-01 2016-03-18 0000802257 tntyob:ConvertiblePromissoryNoteMember 2016-03-18 0000802257 tntyob:ConvertiblePromissoryNoteMember 2016-01-01 2016-03-31 0000802257 tntyob:ConvertiblePromissoryNoteMember 2016-03-31 0000802257 tntyob:August2014ConvertibleDebenturesSeriesCMember 2016-01-01 2016-03-31 0000802257 tntyob:August2014ConvertibleDebenturesSeriesCMember 2016-03-31 0000802257 tntyob:November2014ConvertibleDebenturesSeriesDMember 2016-01-01 2016-03-31 0000802257 tntyob:November2014ConvertibleDebenturesSeriesDMember 2016-03-31 0000802257 us-gaap:RestrictedStockMember tntyob:BoardMember 2016-03-31 0000802257 us-gaap:RestrictedStockMember tntyob:BoardMember 2016-01-01 2016-03-31 0000802257 us-gaap:RestrictedStockMember 2016-01-01 2016-03-31 0000802257 us-gaap:RestrictedStockMember us-gaap:MinimumMember 2016-03-31 0000802257 us-gaap:RestrictedStockMember us-gaap:MaximumMember 2016-03-31 0000802257 us-gaap:SubsequentEventMember us-gaap:BoardOfDirectorsChairmanMember 2016-04-01 2016-04-11 0000802257 us-gaap:SubsequentEventMember tntyob:P3CompoundingOfGeorgiaLlcMember 2016-04-29 0000802257 us-gaap:SubsequentEventMember tntyob:P3CompoundingOfGeorgiaLlcMember 2016-04-01 2016-04-29 0000802257 us-gaap:SubsequentEventMember tntyob:P3CompoundingOfGeorgiaLlcMember us-gaap:IntellectualPropertyMember 2016-04-29 0000802257 us-gaap:SubsequentEventMember tntyob:P3CompoundingOfGeorgiaLlcMember us-gaap:IntellectualPropertyMember 2016-04-01 2016-04-29 0000802257 us-gaap:SubsequentEventMember tntyob:P3CompoundingOfGeorgiaLlcMember us-gaap:VicePresidentMember 2016-04-01 2016-04-29 0000802257 us-gaap:SubsequentEventMember us-gaap:IntellectualPropertyMember 2016-04-29 0000802257 us-gaap:WarrantMember 2015-01-01 2015-03-31 0000802257 us-gaap:WarrantMember 2016-01-01 2016-03-31 0000802257 us-gaap:OptionMember 2016-01-01 2016-03-31 0000802257 us-gaap:OptionMember 2015-01-01 2015-03-31 0000802257 us-gaap:ConvertibleNotesPayableMember 2016-01-01 2016-03-31 0000802257 us-gaap:ConvertibleNotesPayableMember 2015-01-01 2015-03-31 0000802257 tntyob:WilliamLRossAndJeffreyCosmanMember 2016-01-01 2016-01-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 0000802257 10-Q 2016-03-31 false --12-31 No No Yes Smaller Reporting Company Q1 2016 12500000

10000000

500000000

15000

16363

150

16213

-622470

-623745

1 for 101

118679

62128

56551

446965

-390414

-1275

10000

67879

78462

24753

75987

2475

66635

75987

21.40

29.55

30.51

50.50

21.78

30.51

P7Y2M1D

P3Y5M5D

P6Y11M1D P3Y3M15D

P6Y9M26D

P3Y3M15D

18152 74257

3610

45673

Stock options typically vest over a three-year period and have a life of ten years from the date granted.

Stock options typically vest over a three year period and have a life of ten years from the date granted.

780

2019-12-31

177270

0.12 True Nature Holding, Inc.

232056

194699 252266

16000

17250

45185

33479

-519688

-671764

117650

3917

-641255

124000

684078

-1479842

-641255

-1479842

3917

684078

117650

124000

564873

705243

564873

705243

122167

29598

13325

63465

14918 18812

414463

471201

45185

33479

45185

33479

17000

4250

11348

28185

17881

14119

16524

12057500

542605

-0.07

-1.15

-0.07

-838587

-623745

-838587

-622470

-838587

-1275

-838587

6218

-832369

832369

11765000

12400000

11765000

12400000

120000 54000 1200 52800 500000 587500 5000 582500 16364 16364

12284

32577

202916

-10304

2405

204137

-47681

-154051

114000

54000

60000

-124304

54034

56738

-12750

11348

-297500 -290000

2325

12284

-838587

-622470

0.01

11765000

12400000

P1Y

Note 1 Description of Business   True Nature Holding, Inc. (the Company), previously known as Trunity Holdings, Inc., became a publicly-traded company through a reverse merger with Brain Tree International, Inc., a Utah corporation (BTI). Trunity Holdings, Inc. was the parent company of the prior educational business, named Trunity, Inc., which was formed on July 28, 2009 through the acquisition of certain intellectual property by its three founders. On December 31, 2015, the Company completed the restructuring and spin-out of the educational business.   True Nature Holding, Inc. intends to acquire a series of businesses which specialize in compounding pharmacy activities, largely direct to consumers, doctors and veterinary professionals.

Note 3 Financial Condition and Going Concern   As of March 31, 2016, the Company had cash on hand of $17,881 and current liabilities of $705,243 and has incurred a loss from operations. True Nature Holdings planned principal operations pertain to the business development and acquisition of pharmaceutical compounding companies. The Companys activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan.   As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern. The Companys continuance is dependent on raising capital and generating revenues sufficient to sustain operations. The Company believes that the necessary capital will be raised and has entered into discussions to do so with certain individuals and companies. However, as of the date of these consolidated financial statements, no formal agreement exists.   The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

Note 4 Spin-Out and Discontinued Operations   On December 31, 2015, the Company completed the restructuring and spin-out of software educational business, resulting in True Nature Holding, Inc. becoming purely focused on acquiring a series of businesses which specialize in compounding pharmacy activities, largely direct to consumers, doctors and veterinary professionals. The results of the operations associated with the spin-out company and Trunity Holdings, Inc., qualifies as discontinued operations as of and for the three month period ended March 31, 2015.   The results of operations associated with discontinued operations were as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2015</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%">Net Sales</td> <td style="width: 9%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">118,679</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Cost of sales</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">62,128</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross Profit</td> <td> </td> <td> </td> <td style="text-align: right">56,551</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating Expenses:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Research and development</td> <td> </td> <td> </td> <td style="text-align: right">194,699</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 10pt">Selling, general and administrative</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">252,266</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 20pt">Total operating expenses</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">446,965</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Operating Loss from Discontinued Operations</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(390,414</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Other Expense:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 10pt">Interest expense, net</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(232,056</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Net Loss from Discontinued Operations</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(622,470</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Other Comprehensive Loss Net of Tax:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 10pt">Foreign currency translation adjustments</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(1,275</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Comprehensive Loss from Discontinued Operations</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(623,745</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>    Our educational business was fully disposed of in December 2015.  As a result, there were no assets or liabilities of discontinued operations as of 12/31/2015 or 3/31/2016.

Note 5 Related Party Transactions   The Companys Chairman of the Board, CEO and CFO, Stephen Keaveney has a consulting agreement in the amount of $10,000 per month for professional fees and was paid $16,000 during the three months ending March 31, 2016. On January 25, 2016 board member William L. Ross and Jeffrey Cosman were awarded each 100,000 of shares in Trunity, Inc. in exchange for their services as board members. In addition, a shareholder of the Company has a consulting agreement in the amount of $10,000 per month for professional fees and was paid $17,250 during the three months ended March 31, 2016. $4,250 and $17,000 has been classified as a prepaid asset as of March 31, 2016 and December 31, 2015, respectively, in the consolidated balance sheets related to the prepayment of consulting fees.

Note 6 Debt   Convertible Promissory Note   On March 18, 2016, the Company issued a 12% Convertible Promissory Note (the Convertible Note) in the principal amount of $60,000 to the Lender. Pursuant to the terms of the Convertible Note, on the date thereof, the Company issued the Convertible Note to the Lender and, as consideration therefor, the Lender paid the Company in cash the full principal amount of the Convertible Note. Upon issuance the lender was awarded 15,000 restricted common shares as an origination fee which have certain registration rights.   Pursuant to the terms of the Convertible Note, the Company is obligated to pay monthly installments of not less than $1,000 the first of each month commencing the month following the execution of this note until its full maturity on September 16, 2016 at which time the Company is obligated to repay the full principal amount of the Convertible Note. The Convertible Note is convertible by the holder at any time into shares of the Companys common stock at an effective conversion price of $1.00 and throughout the duration of this Convertible Note the holder has the right to participate in any and other financing the Company may engage in with the same terms and option as all other investors. The Company allocated the face value of the Convertible Note to the shares and the note based on relative fair values, and the amount allocated to the shares of $16,364 was recorded as a discount against the note, with an offsetting entry to additional paid-in capital. The beneficial conversion feature of $16,364 was recorded as a debt discount with an offsetting entry to additional paid-in capital decreasing the note payable and increasing debt discount. The debt discount is being amortized to interest expense over the term of the debt. As of March 31, 2016, the carrying value of this Convertible Note was $29,598 and accrued interest expense of $260. For the three months ended March 31, 2016, debt discount amortization related to the Convertible Note was $2,325 and interest expense of $260.   August 2014 Convertible Debentures (Series C)   In fiscal 2015, all debentures issued by Trunity Holdings, Inc. to fund the former educational business were eligible to participate in a debt conversion; however, one debenture holder that was issued a Series C Convertible Debenture (the Series C Debenture) in August 2014 with an aggregate face value of $100,000 in exchange for the cancellation of Series B Convertible Debentures with a carrying value of $110,833 did not convert. The Series C Debenture accrues interest at an annual rate of 10%, matured on October 31, 2015, and is convertible into the Companys common stock at a conversion rate of $20.20 per share. The holders of the Series C Debenture also received warrants to acquire 4,950 shares post-split of common stock for an exercise price of $20.20 per share, exercisable over five years. The former educational business in fiscal 2014 allocated the face value of the Series C Debenture to the warrants and the debentures based on its relative fair values, and allocated to the warrants, which was recorded as a discount against the Series C Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed in fiscal 2014 upon execution of the new debentures. As of March 31, 2016, the carrying value of this Series C Debenture was $110,833 and accrued interest expense of $16,625. For the three months ended March 31, 2016, interest expense related to the Debenture was $3,288.   November 2014 Convertible Debentures (Series D)   In fiscal 2015, all debentures issued by Trunity Holdings, Inc. to fund the former educational business were eligible to participate in a debt conversion however one debenture holder that was issued a Series D Convertible Debenture (the Series D Debenture) in November 2014 with an aggregate face value of $10,000 in exchange for the cancellation of Series B Convertible Debenture with a carrying value of $11,334 that did not participate in the debt conversion restructuring. The Series D Debenture accrues interest at an annual rate of 12%, matured on October 31, 2015, and is convertible into the Companys common stock at a conversion rate of $16.67 per share. The holders of the Series D Debenture also received warrants to acquire 495 shares post-split of common stock for an exercise price of $20.20 per share, exercisable over five years. The former educational business in fiscal 2014 allocated the face value of the Series D Debenture to the warrants and the debentures based on their relative fair values, and allocated to the warrants, which was recorded as a discount against the Series D Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed in fiscal 2014 upon execution of the new debentures. As of March 31, 2016, the carrying value of the Series D Debenture was $11,334 and accrued interest expense of $1,927. For the three months ended March 31, 2016, interest expense related to the Debenture was $346.

Note 7 Stockholders Deficit   Sale of Common Stock  During the quarter ended March 31, 2016, the Company raised gross proceeds of $60,000 through the sale of 120,000 shares of common stock to accredited investors in private placement transactions at a price of $0.50 per share. The Company incurred $6,000 of securities issuance costs representing commissions paid to broker-dealers who assisted with these transactions.   Shares for Consulting Services and Board Members  During the quarter ended March 31, 2016, in connection with services rendered, the Company issued 300,000 restricted shares of the Companys common stock at a value of $1.45 and $0.90 per share in exchange for financial consulting services conducted on behalf of the Company. In addition, in connection with services rendered for board members, the Company issued 200,000 restricted shares of the Companys common stock at a value of $1.45 per share in exchange for their services conducted on behalf of the Company.   Shares issued for convertible note payable  As discussed in Note 6, during the quarter ended March 31, 2016, in connection with conversion of a six-month convertible promissory note, the Company issued 15,000 shares of the Companys common stock with a fair value of $16,363 that was allocated based on the relative fair value of the note and associated shares.   Debt beneficial conversion feature for convertible note payable  During the quarter ended March 31, 2016, the Company raised gross proceeds of $60,000 pursuant to a Convertible Note Payable (Note) that allocated the face value of the Note to the shares and debt based on their relative fair values and, resulted in the recording of beneficial conversion features totaling $16,364 as a discount against the Notes, with an offsetting entry to additional paid-in capital. The discount is being amortized into interest expense over the term of the Note.

Note 8 Stock-Based Compensation   The Company has two Employee, Director and Consultant Stock Option Plans that were not terminated as a result of the fiscal 2015 restructuring of the Company and spin-out and have continued as part of the operations as detailed below.   In fiscal 2015, the option pool pertaining to the 2009 Employee, Director and Consultant Stock Option Plan (the 2009 Plan) was adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan, resulting in an authorized option pool of 18,152. Stock options typically vest over a three-year period and have a life of ten years from the date granted. As of March 31, 2016 there were 3,610 shares available for future awards under this plan.   In fiscal 2015, the option pool pertaining to the 2012 Employee, Director and Consultant Stock Option Plan (the 2012 Plan) was adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan, resulting in an authorized options pool of 74,257. Stock options typically vest over a three year period and have a life of ten years from the date granted. As of March 31, 2016, there were 45,673 shares available for future awards under this plan.   In addition, there are approximately 24,753 in options outstanding that were issued to a former CEO of the Company in fiscal 2014. These options issued are outside of the 2009 and 2012 Plans.   During the quarter ended March 31, 2016, the Company did not grant options to acquire shares of common stock to employees, directors or consultants.   For all previous grants the fair value of options is estimated using the Black-Scholes option pricing model. The expected term of options granted is based on the simplified method in accordance with Securities and Exchange Commission Staff Accounting Bulletin 107, and represents the period of time that options granted are expected to be outstanding. The Company makes assumptions with respect to expected stock price volatility based on the average historical volatility of peers with similar attributes. In addition, the Company determines the risk free rate by selecting the U.S. Treasury with maturities similar to the expected terms of grants, quoted on an investment basis in effect at the time of grant for that business day.   As of March 31, 2016, there was approximately $780 of total unrecognized stock compensation expense, related to unvested stock options under the Plans. This expense is expected to be recognized over the remaining weighted average vesting periods of the outstanding options of less than one year. The Company recorded $12,284 in stock compensation expense to continuing operations within selling, general and administrative expenses on the consolidated statements of operations and comprehensive loss pertaining to the vesting of options in fiscal 2016.   A summary of options issued, exercised and cancelled are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td> </td> <td colspan="3" style="text-align: center">Shares</td> <td> </td> <td colspan="3" style="text-align: center">Weighted- Average Exercise Price ($)</td> <td> </td> <td colspan="3" style="text-align: center">Weighted- Average Remaining Contractual Term</td> <td> </td> <td colspan="3" style="text-align: center">Aggregate Intrinsic Value ($)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%; padding-left: 6.25pt; text-indent: -6.25pt">Outstanding at December 31, 2015</td> <td style="width: 1%; padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">67,879</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">21.40</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">7.17</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right"></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 6.25pt; text-indent: -6.25pt">Granted</td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td> </td> <td> </td> <td style="text-align: right"></td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 6.25pt; text-indent: -6.25pt">Cancelled</td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 6.25pt; text-indent: -6.25pt">Outstanding at March 31, 2016</td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">67,879</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">21.40</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6.92</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"></td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 6.25pt; text-indent: -6.25pt">Exercisable at March 31, 2016</td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">66,635</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">34.75</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6.82</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"></td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Note 9 Warrants to Purchase Common Stock   Subsequent to the restructuring of the Company and the spin-out, the Company had warrants to purchase common stock outstanding that were not terminated and have continued as part of the operations as detailed below. The warrants were adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan as authorized. No warrants were issued during the first quarter ended March 31, 2016. All warrants outstanding as of March 31, 2016 are scheduled to expire at various dates through 2019. A summary of warrants issued, exercised and expired are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td> </td> <td colspan="3" style="text-align: center">Shares</td> <td> </td> <td colspan="3" style="text-align: center">Weighted- Average Exercise Price ($)</td> <td> </td> <td colspan="3" style="text-align: center">Weighted-Average Remaining Contractual Term</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 45%; padding-left: 6.25pt; text-indent: -6.25pt">Outstanding at December 31, 2015</td> <td style="width: 1%; padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="width: 3%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">78,462</td> <td style="width: 1%"> </td> <td style="width: 3%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">29.55</td> <td style="width: 1%"> </td> <td style="width: 3%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">3.43</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 6.25pt; text-indent: -6.25pt">Granted</td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td> </td> <td> </td> <td style="text-align: right"></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 6.25pt; text-indent: -6.25pt">Expired</td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,475</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">50.50</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 6.25pt; text-indent: -6.25pt">Outstanding at March 31, 2016</td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">75,987</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">30.51</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3.29</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 6.25pt; text-indent: -6.25pt">Exercisable at March 31, 2016</td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">75,987</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">30.51</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3.29</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Note 10 Commitments and Contingencies   Legal   National Council for Science and the Environment, Inc. v. Trunity Holdings, Inc., Case No.. 2015 CA 009726 B, Superior Court for the District of Columbia, Civil Division.   This action was filed on December 16, 2015 by the National Council for Science and the Environment, Inc. (NCSE) in the state court in the District of Columbia against Trunity Holdings, Inc. (Trunity) and alleges claims for Breach of Contract. Acknowledgement of Indebtedness and Settlement Agreement and Quantum Meruit arising out of an agreement entered into between NCSE and Trunity in 2014. The Complaint seeks damages in the amount of $177,270, inclusive of attorneys fees, costs and accrued interest, continuing interest in the amount of 12% per annum and attorneys fees and costs of collection relating to the case. The Company in its answer on January 27, 2016, denied the material allegations made by NCSE, asserted a number of affirmative defenses and filed a counterclaim alleging claims for fraud, negligent misrepresentation, breach of fiduciary duty, breach of contract and unjust enrichment. In its counterclaim, the Company will seek actual and compensatory damages against NCSE that it believes exceed the amount sought by NCSE on its claims, pre-judgment interest, punitive damages and all costs and expenses, including attorneys fees, incurred by the Company in bringing its claims against NCSE.   On February 19, 2016, NCSE filed a motion to dismiss the counterclaim, and the Company has filed its brief in the opposition to that motion. A hearing is scheduled in second quarter 2016 on the motion. No discovery has been conducted by the parties yet, and no trial date has been set by the court. We have recorded a liability as of March 31, 2016 based on our best estimate of the probable exposure pertaining to the claim.

Note 11 Subsequent Events   On April 4, 2016 the Company entered into a non-binding letter of intent to acquire a compounding pharmacy in Holly Springs, Georgia, a suburb of Atlanta. The agreement calls for purchase consideration of approximately $450,000. Payment will be split between the issuance of common stock, a convertible note that may convert into stock at a price not less than $2 per share. The final allocation of each of these will be determined prior to closing, which is expected to occur in June 2016. The letter of intent is not a definitive agreement, and the Company anticipates that the definitive agreement will contain customary conditions to closing.   On April 11, 2016 the Board of Directors elected Mr. James Driscoll, age 54, to the Board of Directors. Mr. Driscoll is currently CEO of Channel Terminals, LLC, a crude oil liquids terminals and refinery based in Houston, TX. Mr. Driscoll is also a member of the Board of Directors at Double Zero Recycling LLC as well as an Advisory Board Member at HealPros LLC, a diabetic retinal imaging business, and Funding University LLC, an early stage online peer to peer lending business targeted on secondary education. Previously he was President of Method Holdings, LLC, from 2011 until late 2013. Between 2006 and 2011 Mr. Driscoll was a Senior Partner with private equity firm 1848 Capital Partners LLC. From 2009 to 2010 he was COO and Executive Vice President of CareDynamix LLC, a healthcare business focused on provision of onsite vaccination services around the US. In addition, Mr. Driscoll, has over 14 years of experience at various senior positions in the power generation and transportation industries in varied locations around the world. He began his professional career as a trader in New York City. He has an MBA from Harvard University (1991) and a BA in English Literature from Bowdoin College (1984). Mr. Driscoll will receive 100,000 shares of restricted common stock as compensation for his term on the Board, consistent with all prior appointments by the Company.   On April 11, 2016, Dr. William Ross, age 70, advised the Company that he desired to resign from the Board of Directors, as he intends to retire from all business activities. There were no disagreements, or conflicts with the Board and Dr. Ross.   On April 29, 2016, subject to approval by the Georgia Board of Pharmacy, the Company entered into definitive documents to acquire P3 Compounding of Georgia, LLC,following the letter of intent dated March 29, 2016. The total consideration for the transaction is $1,000,000. The transaction includes the acquisition of certain special formulations as Intellectual Properties.   The consideration paid was comprised of three (3) components: 1)     the business interests were acquired in consideration of a) $425,000 of convertible notes with a conversion price of $1.25 per share and interest of 6% and b) a short term note in the amount of $75,000, non-interest bearing, with a maturity of June 16, 2016; 2)     the specialized formulations of the business, which will be included in the Companys library of Intellectual Properties, were acquired in consideration a) $425,000 of convertible notes with a conversion price of $1.25 per share and interest of 6% and b) a short term note in the amount of $75,000, non-interest bearing, with a maturity of June 16, 2016; 3)     Mr. Casey Gaetano, employed under a 3 year employment contract as VP of Corporate Development, at an annual salary of $125,000, plus normal benefits commensurate with other executives in the Company of equal stature. He will also receive 125,000 shares of restricted stock in the amount.   The notes issued in conjunction with the purchase and the intellectual properties may be converted into restricted common stock at a rate of $1.25 per share. The purchase includes all payables, receivables, cash on hand, inventory and all assets used in the operation of the business.

Basis of Presentation - The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information, with the instructions to Form 10-Q and with Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required for complete financial statements. In the opinion of management, these consolidated financial statements contain all normal recurring adjustments considered necessary for a fair presentation of the Companys financial position at March 31, 2016, the results of operations for the three months ended March 31, 2016 and 2015, and cash flows for the three months ended March 31, 2016 and 2015. The results for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the full year. These statements should be read in conjunction with the Companys audited consolidated financial statements and managements discussion and analysis included in the Companys annual report on Form 10-K for the year ended December 31, 2015. In addition, refer to Note 4 regarding the spin-out of the educational business and related discontinued operations classification pertaining to the fiscal 2015 period. Common stock share and per share amounts in these financial statements have been retroactively adjusted for the effects of a 1 for 101 reverse stock split that occurred in January 2016.

Use of Estimates - The preparation of these financial statements requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and related notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment.

The results of operations associated with discontinued operations were as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2015</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%">Net Sales</td> <td style="width: 9%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">118,679</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Cost of sales</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">62,128</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross Profit</td> <td> </td> <td> </td> <td style="text-align: right">56,551</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating Expenses:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Research and development</td> <td> </td> <td> </td> <td style="text-align: right">194,699</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 10pt">Selling, general and administrative</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">252,266</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 20pt">Total operating expenses</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">446,965</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Operating Loss from Discontinued Operations</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(390,414</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Other Expense:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 10pt">Interest expense, net</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(232,056</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Net Loss from Discontinued Operations</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(622,470</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Other Comprehensive Loss Net of Tax:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 10pt">Foreign currency translation adjustments</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(1,275</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Comprehensive Loss from Discontinued Operations</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(623,745</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>

A summary of options issued, exercised and cancelled are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td> </td> <td colspan="3" style="text-align: center">Shares</td> <td> </td> <td colspan="3" style="text-align: center">Weighted- Average Exercise Price ($)</td> <td> </td> <td colspan="3" style="text-align: center">Weighted- Average Remaining Contractual Term</td> <td> </td> <td colspan="3" style="text-align: center">Aggregate Intrinsic Value ($)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%; padding-left: 6.25pt; text-indent: -6.25pt">Outstanding at December 31, 2015</td> <td style="width: 1%; padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">67,879</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">21.40</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">7.17</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right"></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 6.25pt; text-indent: -6.25pt">Granted</td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td> </td> <td> </td> <td style="text-align: right"></td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 6.25pt; text-indent: -6.25pt">Cancelled</td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 6.25pt; text-indent: -6.25pt">Outstanding at March 31, 2016</td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">67,879</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">21.40</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6.92</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"></td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 6.25pt; text-indent: -6.25pt">Exercisable at March 31, 2016</td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">66,635</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">34.75</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6.82</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"></td> <td style="padding-bottom: 2.5pt"> </td></tr></table>

A summary of warrants issued, exercised and expired are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td> </td> <td colspan="3" style="text-align: center">Shares</td> <td> </td> <td colspan="3" style="text-align: center">Weighted- Average Exercise Price ($)</td> <td> </td> <td colspan="3" style="text-align: center">Weighted-Average Remaining Contractual Term</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 45%; padding-left: 6.25pt; text-indent: -6.25pt">Outstanding at December 31, 2015</td> <td style="width: 1%; padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="width: 3%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">78,462</td> <td style="width: 1%"> </td> <td style="width: 3%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">29.55</td> <td style="width: 1%"> </td> <td style="width: 3%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">3.43</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 6.25pt; text-indent: -6.25pt">Granted</td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td> </td> <td> </td> <td style="text-align: right"></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 6.25pt; text-indent: -6.25pt">Expired</td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,475</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">50.50</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 6.25pt; text-indent: -6.25pt">Outstanding at March 31, 2016</td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">75,987</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">30.51</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3.29</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 6.25pt; text-indent: -6.25pt">Exercisable at March 31, 2016</td> <td style="padding-left: 6.25pt; text-indent: -6.25pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">75,987</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">30.51</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 6.25pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3.29</td> </tr></table>

60000

10000 100000 16364

15000

0.12

0.10

0.12

2015-10-31

2016-09-16

2016-06-16

16.67

20.20

1.25

1.00

1.25

495

4950

20.20

P5Y P5Y 11334 110833 29598 110833 11334

260

16625

1927

16364

2325

1000

0.50

1.45

0.90

1.45

6000

200000

300000

16364

120000

60000

260

3288

346

450000

1000000

100000

125000

425000

0.06

75000

125000

166415

78462

67879

68473

7105

223223

100000

Note 2 Summary of Significant Accounting Policies   Basis of Presentation - The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information, with the instructions to Form 10-Q and with Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required for complete financial statements. In the opinion of management, these consolidated financial statements contain all normal recurring adjustments considered necessary for a fair presentation of the Companys financial position at March 31, 2016, the results of operations for the three months ended March 31, 2016 and 2015, and cash flows for the three months ended March 31, 2016 and 2015. The results for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the full year. These statements should be read in conjunction with the Companys audited consolidated financial statements and managements discussion and analysis included in the Companys annual report on Form 10-K for the year ended December 31, 2015. In addition, refer to Note 4 regarding the spin-out of the educational business and related discontinued operations classification pertaining to the fiscal 2015 period. Common stock share and per share amounts in these financial statements have been retroactively adjusted for the effects of a 1 for 101 reverse stock split that occurred in January 2016.   Use of Estimates - The preparation of these financial statements requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and related notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment.   Per Share Data - Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the year. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents (if dilutive) related to warrants, options and convertible instruments.    The Company has excluded all common equivalent shares outstanding for warrants, options and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of March 31, 2016, the Company had 78,462 warrants, 67,879 options, 7,105 potential shares which may be issued resulting from the provisions of convertible notes, respectively. As of March 31, 2015, the Company had 166,415 warrants, 68,473 options, 223,223 potential shares which may be issued resulting from the provisions of convertible notes, respectively.   Recently Issued Accounting Standards-In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers. This updated guidance supersedes the current revenue recognition guidance, including industry-specific guidance. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The updated guidance is effective for interim and annual periods beginning after December 15, 2016, and early adoption is not permitted. In July 2015, the FASB decided to delay the effective date of ASU 2014-09 until December 15, 2017. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The Company is currently evaluating which transition method it will adopt and the expected impact of the updated guidance, but does not believe the adoption of the updated guidance will have a significant impact on its consolidated financial statements.   In February 2016, the FASB issued ASU 2016-02, Leases, which requires the lease rights and obligations arising from lease contracts, including existing and new arrangements, to be recognized as assets and liabilities on the balance sheet. ASU 2016-02 is effective for reporting periods beginning after December 15, 2018 with early adoption permitted. While the Company is still evaluating ASU 2016-02, the Company expects the adoption of ASU 2016-02 to have a material effect on the Companys consolidated balance sheets and results of operations due to the recognition of the lease rights and obligations as assets and liabilities. The Company does not expect ASU 2016-02 to have a material effect on the Companys cash flows.   In January 2016, the FASB issued ASU 2016-01, Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities, which addresses certain aspects of recognition, measurement, presentation and disclosure of financial statements. This guidance will be effective in the first quarter of fiscal year 2019 and early adoption is not permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.   In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which addresses certain aspects of accounting for share-based payment award transactions. This guidance will be effective in the first quarter of fiscal year 2017 and early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.

Per Share Data - Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the year. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents (if dilutive) related to warrants, options and convertible instruments.    The Company has excluded all common equivalent shares outstanding for warrants, options and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of March 31, 2016, the Company had 78,462 warrants, 67,879 options, 7,105 potential shares which may be issued resulting from the provisions of convertible notes, respectively. As of March 31, 2015, the Company had 166,415 warrants, 68,473 options, 223,223 potential shares which may be issued resulting from the provisions of convertible notes, respectively.

Recently Issued Accounting Standards-In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers. This updated guidance supersedes the current revenue recognition guidance, including industry-specific guidance. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The updated guidance is effective for interim and annual periods beginning after December 15, 2016, and early adoption is not permitted. In July 2015, the FASB decided to delay the effective date of ASU 2014-09 until December 15, 2017. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The Company is currently evaluating which transition method it will adopt and the expected impact of the updated guidance, but does not believe the adoption of the updated guidance will have a significant impact on its consolidated financial statements.   In February 2016, the FASB issued ASU 2016-02, Leases, which requires the lease rights and obligations arising from lease contracts, including existing and new arrangements, to be recognized as assets and liabilities on the balance sheet. ASU 2016-02 is effective for reporting periods beginning after December 15, 2018 with early adoption permitted. While the Company is still evaluating ASU 2016-02, the Company expects the adoption of ASU 2016-02 to have a material effect on the Companys consolidated balance sheets and results of operations due to the recognition of the lease rights and obligations as assets and liabilities. The Company does not expect ASU 2016-02 to have a material effect on the Companys cash flows.   In January 2016, the FASB issued ASU 2016-01, Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities, which addresses certain aspects of recognition, measurement, presentation and disclosure of financial statements. This guidance will be effective in the first quarter of fiscal year 2019 and early adoption is not permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.   In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which addresses certain aspects of accounting for share-based payment award transactions. This guidance will be effective in the first quarter of fiscal year 2017 and early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.

EX-101.SCH 6 tntyob-20160331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Unaudited Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Unaudited Consolidated Statements of Changes in Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Unaudited Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Note 1 - Description of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Note 3 - Financial Condition and Going Concern link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Note 4 - Spin-Out and Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Note 5 - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Note 6 - Debt link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Note 7 - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Note 8 - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Note 9 - Warrants to Purchase Common Stock link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Note 10 - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Note 11 - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Note 4 - Spin-Out and Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Note 9 - Warrants to Purchase Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Note 3 - Financial Condition and Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Note 4 - Spin-Out and Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Note 5 - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Note 6 - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Note 7 - Stockholders' Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Note 8 - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Note 8 - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Note 9 - Warrants to Purchase Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Note 9 - Warrants to Purchase Common Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Note 10 - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Note 11 - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 tntyob-20160331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 tntyob-20160331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 tntyob-20160331_lab.xml XBRL LABEL FILE Common Stock Equity Components [Axis] Additional Paid-in Capital Accumulated Comprehensive Income Accumulated Deficit Internal costs capitalized for the twelve months ended December 31, 2012 Report Date [Axis] Internal costs capitalized for the twelve months ended December 31, 2013 Internal costs capitalized for the twelve months ended December 31, 2014 Internal costs capitalized for the nine months ended September 30, 2015 Mrs. Fernandez-McGovern [Member] Related Party [Axis] Series F Convertible Debenture [Member] Debt Instrument [Axis] July 2014 Convertible Promissory Note [Member] Joakim Lindblom [Member] Series D Convertible Debenture [Member] Les Anderton [Member] Series E Convertible Debentures [Member] Ivan Berkowitz [Member] Series D and Series E Convertible Debentures [Member] July to November 2014 Convertible Debentures Long-term Debt, Type [Axis] Series B Debentures [Member] Investment Securities Class [Axis] July Notes Convertible Debenture November and December 2014 Unsecured Redeemable Debentures October and November Notes Series A Debentures [Member] Canadian Dollars [Member] Currency [Axis] January-September 2015 Unsecured Redeemable Debentures Potential shares [Member] Series C Debentures [Member] Series D Debentures [Member] Series E Debentures [Member] Series F Debentures [Member] Total Debentures [Member] Convertible Promissory Note [member] August 2014 and November Convertible Debentures November 2014 Convertible Debenture July 2014 Convertible Notes Series B Debentures-Issuance II November 2014 Convertible Peak Debenture [Member] CEO and CFO [Member] Title of Individual [Axis] January-March 2015 Unsecured Redeemable Debentures Officer and Board Member [Member] August and September 2012 Notes July 2014 Convertible Promissory Notes Minimum [Member] Range [Axis] Maximum [Member] Mr. Buntzman's Warrant [Member] Award Type [Axis] Employee, Director and Consultant Plan Name [Axis] 2009 Employee, Director and Consultant Stock Option Plan (the " 2009 Plan") 2012 Employee, Director and Consultant Stock Option Plan (the "2012 Plan") Tranche 1 Investment Contract Counterparty [Axis] Tranche 2 Tranche 3 Exercise Price Range [Axis] Options [Member] Antidilutive Securities [Axis] Convertible Debt [Member] Preferred Stock Accumulated Comprehensive Loss N4P [Member] Legal Entity [Axis] Trunity Holdings, Inc. [Member] Stephen Keaveney [Member] Shareholder [Member] Board member [Member] November 2014 Convertible Debentures (Series D) [Member] November 2014 Convertible Debentures (Series B) [Member] August 2014 Convertible Debentures (Series C) [Member] August 2014 Convertible Debentures (Series B) [Member] Legacy shareholders [Member] Various individuals [Member] Chief Executive Officer [Member] Subsequent Event [Member] Subsequent Event Type [Axis] Newco4pharmacy, LLC [Member] Convertible Promissory Note [Member] Restricted Stock [Member] Board Member [Member] Common Stock [Member] Mr. James Driscoll [Member] P3 Compounding of Georgia, LLC [Member] Intellectual Properties [Member] Finite-Lived Intangible Assets by Major Class [Axis] Mr. Casey Gaetano [Member] Warrants [Member] Options [Member] Potential shares [Member] William L. Ross and Jeffrey Cosman [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer Is Entity a Voluntary Filer Is Entity's Reporting Status Current Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash and Cash Equivalents Prepaid expenses Prepaid expenses - related party Total current assets TOTAL ASSETS LIABILITIES Current liabilities Accounts payable Accrued interest Accrued liabilities Convertible note payable, net of discount Debentures payable Total current liabilities TOTAL LIABILITIES Commitments and Contingencies (Note 10) STOCKHOLDERS' DEFICIT Preferred stock, $0.01 par value - 10,000,000 shares authorized, none issued and outstanding as of March 31, 2016 and December 31, 2015 Common stock, $0.01 par value - 500,000,000 shares authorized, 12,400,000 shares issued and outstanding at March 31, 2016; $0.01 par value - 500,000,000 shares authorized, 11,765,000 shares issued and outstanding at December 31, 2015 Additional paid-in capital Accumulated deficit Total Stockholders' Deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Preferred stock par value Preferred stock shares authorized Preferred stock shares issued Preferred stock shares outstanding Common stock par value Common stock shares authorized Common stock shares issued Common stock shares outstanding Income Statement [Abstract] Net Sales Cost of sales Gross Profit Operating expenses: Research and development Selling, general and administrative Total operating expenses Operating Loss from Continuing Operations Interest expense, net Loss From Continuing Operations before Income Taxes Provision for income taxes Net Loss From Continuing Operations Discontinued Operations (Note 4): Net Loss from discontinued operations, net of tax Other comprehensive loss, net of tax Comprehensive Loss from Discontinued Operations Net Loss Comprehensive Net Loss Net Loss from Continuing Operations Per Share - Basic and Diluted Net Loss from Discontinued Operations Per Share - Basic and Diluted Net Loss Per Share - Basic and Diluted Weighted Average Number of Shares Outstanding During the Period - Basic and Diluted Statement [Table] Statement [Line Items] Beginning Balance, Amount Beginning Balance, Shares Sale of common stock, net of issuance cost, Amount Sale of common stock, net of issuance cost, Shares Shares issued to board members and consultants, Amount Shares issued to board members and consultants, Shares Common stock issued for convertible note payable, Amount Common stock issued for convertible note payable, Shares Discount related to issuance of note payable and allocated fair value to beneficial conversion feature Stock compensation expense Net loss Ending Balance, Amount Ending Balance, Shares Statement of Cash Flows [Abstract] Cash Flows from Operating Activities: Net Loss Adjustments to reconcile net loss to net cash used in operating activities: Loss from discontinued operations Stock-based compensation Accretion for debt discounts, warrants and issuance costs Shares issued for board of director compensation Shares issued for consulting services Changes in operating assets and liabilities: EX-101.PRE 10 tntyob-20160331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	May. 19, 2016
Document And Entity Information
Entity Registrant Name	True Nature Holding, Inc.
Entity Central Index Key	0000802257
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer	No
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		12,500,000
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2016

XML 12 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (unaudited) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
CURRENT ASSETS
Cash and Cash Equivalents	$ 17,881	$ 28,185
Prepaid expenses	11,348
Prepaid expenses - related party	4,250	$ 17,000
Total current assets	33,479	45,185
TOTAL ASSETS	33,479	45,185
Current liabilities
Accounts payable	471,201	414,463
Accrued interest	18,812	14,918
Accrued liabilities	63,465	$ 13,325
Convertible note payable, net of discount	29,598
Debentures payable	122,167	$ 122,167
Total current liabilities	705,243	564,873
TOTAL LIABILITIES	$ 705,243	$ 564,873
Commitments and Contingencies (Note 10)
STOCKHOLDERS' DEFICIT
Preferred stock, $0.01 par value - 10,000,000 shares authorized, none issued and outstanding as of March 31, 2016 and December 31, 2015
Common stock, $0.01 par value - 500,000,000 shares authorized, 12,400,000 shares issued and outstanding at March 31, 2016; $0.01 par value - 500,000,000 shares authorized, 11,765,000 shares issued and outstanding at December 31, 2015	$ 124,000	$ 117,650
Additional paid-in capital	684,078	3,917
Accumulated deficit	(1,479,842)	(641,255)
Total Stockholders' Deficit	(671,764)	(519,688)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 33,479	$ 45,185

XML 13 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock par value	$ 0.01	$ 0.01
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock par value	$ 0.01	$ 0.01
Common stock shares authorized	500,000,000	500,000,000
Common stock shares issued	12,400,000	11,765,000
Common stock shares outstanding	12,400,000	11,765,000

XML 14 R4.htm IDEA: XBRL DOCUMENT

Unaudited Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Net Sales
Cost of sales
Gross Profit
Operating expenses:
Research and development
Selling, general and administrative	$ 832,369
Total operating expenses	832,369
Operating Loss from Continuing Operations	(832,369)
Interest expense, net	(6,218)
Loss From Continuing Operations before Income Taxes	$ (838,587)
Provision for income taxes
Net Loss From Continuing Operations	$ (838,587)
Discontinued Operations (Note 4):
Net Loss from discontinued operations, net of tax		$ (622,470)
Other comprehensive loss, net of tax		(1,275)
Comprehensive Loss from Discontinued Operations		(623,745)
Net Loss	$ (838,587)	(622,470)
Comprehensive Net Loss	$ (838,587)	$ (623,745)
Net Loss from Continuing Operations Per Share - Basic and Diluted	$ (0.07)
Net Loss from Discontinued Operations Per Share - Basic and Diluted		$ (1.15)
Net Loss Per Share - Basic and Diluted	$ (0.07)	$ (1.15)
Weighted Average Number of Shares Outstanding During the Period - Basic and Diluted	12,057,500	542,605

XML 15 R5.htm IDEA: XBRL DOCUMENT

Unaudited Consolidated Statements of Changes in Stockholders' Deficit - 3 months ended Mar. 31, 2016 - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2015	$ 117,650	$ 3,917	$ (641,255)	$ (519,688)
Beginning Balance, Shares at Dec. 31, 2015	11,765,000			11,765,000
Sale of common stock, net of issuance cost, Amount	$ 1,200	52,800		$ 54,000
Sale of common stock, net of issuance cost, Shares	120,000
Shares issued to board members and consultants, Amount	$ 5,000	582,500		587,500
Shares issued to board members and consultants, Shares	500,000
Common stock issued for convertible note payable, Amount	$ 150	16,213		$ 16,363
Common stock issued for convertible note payable, Shares	15,000			15,000
Discount related to issuance of note payable and allocated fair value to beneficial conversion feature		16,364		$ 16,364
Stock compensation expense		$ 12,284		12,284
Net loss			$ (838,587)	(838,587)
Ending Balance, Amount at Mar. 31, 2016	$ 124,000	$ 684,078	$ (1,479,842)	$ (671,764)
Ending Balance, Shares at Mar. 31, 2016	12,400,000			12,400,000

XML 16 R6.htm IDEA: XBRL DOCUMENT

Unaudited Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash Flows from Operating Activities:
Net Loss	$ (838,587)	$ (622,470)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss from discontinued operations		$ 622,470
Stock-based compensation	$ 12,284
Accretion for debt discounts, warrants and issuance costs	2,325
Shares issued for board of director compensation	290,000
Shares issued for consulting services	297,500
Changes in operating assets and liabilities:
Prepaid expenses	(11,348)
Prepaid expenses - related party	12,750
Accounts payable	56,738
Accrued interest and other liabilities	54,034
Net Cash Used in Operating Activities	(124,304)
Cash Flows from Financing Activities:
Proceeds from issuance of convertible note payable	60,000
Sale of common stock, net of issuance costs	54,000
Net Cash Provided by Financing Activities	$ 114,000
Discontinued Operations:
Operating activities		$ (154,051)
Investing activities		(47,681)
Financing activities		204,137
Net Increase in Cash and Cash Equivalents for Discontinued Operations		$ 2,405
Net Decrease in Cash and Cash Equivalents for Continuing Operations	$ (10,304)
Cash, Beginning of Period	28,185	$ 14,119
Cash, End of Period	17,881	16,524
Non-cash Financing Transactions:
Discount cost related to issuance of convertible note payable	$ 32,577	$ 202,916

XML 17 R7.htm IDEA: XBRL DOCUMENT

Note 1 - Description of Business

3 Months Ended

Mar. 31, 2016

Note 1 - Description of Business

Note 1 - Description of Business

Note 1 – Description of Business

True Nature Holding, Inc. intends to acquire a series of businesses which specialize in compounding pharmacy activities, largely direct to consumers, doctors and veterinary professionals.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2016

Note 2 - Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

XML 19 R9.htm IDEA: XBRL DOCUMENT

Note 3 - Financial Condition and Going Concern

3 Months Ended

Mar. 31, 2016

Note 3 - Financial Condition and Going Concern

Note 3 - Financial Condition and Going Concern

Note 3 – Financial Condition and Going Concern

XML 20 R10.htm IDEA: XBRL DOCUMENT

Note 4 - Spin-Out and Discontinued Operations

3 Months Ended

Mar. 31, 2016

Note 4 - Spin-Out and Discontinued Operations

Note 4 - Spin-Out and Discontinued Operations

Note 4 – Spin-Out and Discontinued Operations

The results of operations associated with discontinued operations were as follows:

	March 31,
	2015
Net Sales	$	118,679
Cost of sales		62,128
Gross Profit		56,551

Operating Expenses:
Research and development		194,699
Selling, general and administrative		252,266
Total operating expenses		446,965

Operating Loss from Discontinued Operations		(390,414	)

Other Expense:
Interest expense, net		(232,056	)

Net Loss from Discontinued Operations	$	(622,470	)
Other Comprehensive Loss Net of Tax:
Foreign currency translation adjustments		(1,275	)
Comprehensive Loss from Discontinued Operations	$	(623,745	)

Our educational business was fully disposed of in December 2015. As a result, there were no assets or liabilities of discontinued operations as of 12/31/2015 or 3/31/2016.

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51719941&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721683-107760

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Note 5 - Related Party Transactions

3 Months Ended

Mar. 31, 2016

Note 5 - Related Party Transactions

Note 5 - Related Party Transactions

Note 5 – Related Party Transactions

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

XML 22 R12.htm IDEA: XBRL DOCUMENT

Note 6 - Debt

3 Months Ended

Mar. 31, 2016

Note 6 - Debt

Note 6 - Debt

Note 6 – Debt

Convertible Promissory Note

August 2014 Convertible Debentures (Series C)

November 2014 Convertible Debentures (Series D)

XML 23 R13.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Deficit

3 Months Ended

Mar. 31, 2016

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit

Note 7 – Stockholders’ Deficit

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

Note 8 - Stock-Based Compensation

3 Months Ended

Mar. 31, 2016

Note 8 - Stock-Based Compensation

Note 8 - Stock-Based Compensation

Note 8 – Stock-Based Compensation

In addition, there are approximately 24,753 in options outstanding that were issued to a former CEO of the Company in fiscal 2014. These options issued are outside of the 2009 and 2012 Plans.

During the quarter ended March 31, 2016, the Company did not grant options to acquire shares of common stock to employees, directors or consultants.

A summary of options issued, exercised and cancelled are as follows:

	Shares		Weighted- Average Exercise Price ($)		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value ($)
Outstanding at December 31, 2015		67,879	$	21.40		7.17		—
Granted		—		—		—		—
Cancelled		—		—		—		—

Outstanding at March 31, 2016		67,879	$	21.40		6.92		—

Exercisable at March 31, 2016		66,635	$	34.75		6.82		—

XML 25 R15.htm IDEA: XBRL DOCUMENT

Note 9 - Warrants to Purchase Common Stock

3 Months Ended

Mar. 31, 2016

Note 9 - Warrants to Purchase Common Stock

Note 9 - Warrants to Purchase Common Stock

Note 9 – Warrants to Purchase Common Stock

	Shares		Weighted- Average Exercise Price ($)		Weighted-Average Remaining Contractual Term
Outstanding at December 31, 2015		78,462	$	29.55		3.43
Granted		—		—		—
Expired		2,475		50.50		—

Outstanding at March 31, 2016		75,987	$	30.51		3.29

Exercisable at March 31, 2016		75,987	$	30.51		3.29

XML 26 R16.htm IDEA: XBRL DOCUMENT

Note 10 - Commitments and Contingencies

3 Months Ended

Mar. 31, 2016

Note 10 - Commitments and Contingencies

Note 10 - Commitments and Contingencies

Note 10 – Commitments and Contingencies

Legal

National Council for Science and the Environment, Inc. v. Trunity Holdings, Inc., Case No.. 2015 CA 009726 B, Superior Court for the District of Columbia, Civil Division.

XML 27 R17.htm IDEA: XBRL DOCUMENT

Note 11 - Subsequent Events

3 Months Ended

Mar. 31, 2016

Note 11 - Subsequent Events

Note 11 - Subsequent Events

Note 11 – Subsequent Events

The consideration paid was comprised of three (3) components:

XML 28 R18.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Note 2 - Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation - The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information, with the instructions to Form 10-Q and with Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required for complete financial statements. In the opinion of management, these consolidated financial statements contain all normal recurring adjustments considered necessary for a fair presentation of the Company’s financial position at March 31, 2016, the results of operations for the three months ended March 31, 2016 and 2015, and cash flows for the three months ended March 31, 2016 and 2015. The results for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the full year. These statements should be read in conjunction with the Company’s audited consolidated financial statements and management’s discussion and analysis included in the Company’s annual report on Form 10-K for the year ended December 31, 2015. In addition, refer to Note 4 regarding the spin-out of the educational business and related discontinued operations classification pertaining to the fiscal 2015 period. Common stock share and per share amounts in these financial statements have been retroactively adjusted for the effects of a 1 for 101 reverse stock split that occurred in January 2016.
Use of Estimates	Use of Estimates - The preparation of these financial statements requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and related notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment.
Per Share Data	Per Share Data - Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the year. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents (if dilutive) related to warrants, options and convertible instruments. The Company has excluded all common equivalent shares outstanding for warrants, options and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of March 31, 2016, the Company had 78,462 warrants, 67,879 options, 7,105 potential shares which may be issued resulting from the provisions of convertible notes, respectively. As of March 31, 2015, the Company had 166,415 warrants, 68,473 options, 223,223 potential shares which may be issued resulting from the provisions of convertible notes, respectively.
Recently Issued Accounting Standards	Recently Issued Accounting Standards-In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. This updated guidance supersedes the current revenue recognition guidance, including industry-specific guidance. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The updated guidance is effective for interim and annual periods beginning after December 15, 2016, and early adoption is not permitted. In July 2015, the FASB decided to delay the effective date of ASU 2014-09 until December 15, 2017. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The Company is currently evaluating which transition method it will adopt and the expected impact of the updated guidance, but does not believe the adoption of the updated guidance will have a significant impact on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases, which requires the lease rights and obligations arising from lease contracts, including existing and new arrangements, to be recognized as assets and liabilities on the balance sheet. ASU 2016-02 is effective for reporting periods beginning after December 15, 2018 with early adoption permitted. While the Company is still evaluating ASU 2016-02, the Company expects the adoption of ASU 2016-02 to have a material effect on the Company’s consolidated balance sheets and results of operations due to the recognition of the lease rights and obligations as assets and liabilities. The Company does not expect ASU 2016-02 to have a material effect on the Company’s cash flows. In January 2016, the FASB issued ASU 2016-01, Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities, which addresses certain aspects of recognition, measurement, presentation and disclosure of financial statements. This guidance will be effective in the first quarter of fiscal year 2019 and early adoption is not permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which addresses certain aspects of accounting for share-based payment award transactions. This guidance will be effective in the first quarter of fiscal year 2017 and early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.

XML 29 R19.htm IDEA: XBRL DOCUMENT

Note 4 - Spin-Out and Discontinued Operations (Tables)

3 Months Ended

Mar. 31, 2016

Note 4 - Spin-Out and Discontinued Operations

Results of operations associated with discontinued operations

The results of operations associated with discontinued operations were as follows:

	March 31,
	2015
Net Sales	$	118,679
Cost of sales		62,128
Gross Profit		56,551

Operating Expenses:
Research and development		194,699
Selling, general and administrative		252,266
Total operating expenses		446,965

Operating Loss from Discontinued Operations		(390,414	)

Other Expense:
Interest expense, net		(232,056	)

Net Loss from Discontinued Operations	$	(622,470	)
Other Comprehensive Loss Net of Tax:
Foreign currency translation adjustments		(1,275	)
Comprehensive Loss from Discontinued Operations	$	(623,745	)

XML 30 R20.htm IDEA: XBRL DOCUMENT

Note 8 - Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2016

Note 8 - Stock-Based Compensation

Summary of options issued, exercised and cancelled

A summary of options issued, exercised and cancelled are as follows:

	Shares		Weighted- Average Exercise Price ($)		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value ($)
Outstanding at December 31, 2015		67,879	$	21.40		7.17		—
Granted		—		—		—		—
Cancelled		—		—		—		—

Outstanding at March 31, 2016		67,879	$	21.40		6.92		—

Exercisable at March 31, 2016		66,635	$	34.75		6.82		—

XML 31 R21.htm IDEA: XBRL DOCUMENT

Note 9 - Warrants to Purchase Common Stock (Tables)

3 Months Ended

Mar. 31, 2016

Note 9 - Warrants to Purchase Common Stock

Summary of warrants issued, exercised and expired

A summary of warrants issued, exercised and expired are as follows:

	Shares		Weighted- Average Exercise Price ($)		Weighted-Average Remaining Contractual Term
Outstanding at December 31, 2015		78,462	$	29.55		3.43
Granted		—		—		—
Expired		2,475		50.50		—

Outstanding at March 31, 2016		75,987	$	30.51		3.29

Exercisable at March 31, 2016		75,987	$	30.51		3.29

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 32 R22.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details Narrative) - shares	1 Months Ended	3 Months Ended
	Jan. 31, 2016	Mar. 31, 2016	Mar. 31, 2015
Reverse spilit	1 for 101
Warrant [Member]
Antidilutive securities excluded from computation of earnings per share, amount		78,462	166,415
Options [Member]
Antidilutive securities excluded from computation of earnings per share, amount		67,879	68,473
Potential shares [Member]
Antidilutive securities excluded from computation of earnings per share, amount		7,105	223,223

XML 33 R23.htm IDEA: XBRL DOCUMENT

Note 3 - Financial Condition and Going Concern (Details Narrative) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Note 3 - Financial Condition and Going Concern
Cash and Cash Equivalents	$ 17,881	$ 28,185	$ 16,524	$ 14,119
Current liabilities	$ 705,243	$ 564,873

XML 34 R24.htm IDEA: XBRL DOCUMENT

Note 4 - Spin-Out and Discontinued Operations (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Note 4 - Spin-Out and Discontinued Operations
Net Sales		$ 118,679
Cost of sales		62,128
Gross Profit		56,551
Operating expenses:
Research and development		194,699
Selling, general and administrative		252,266
Total operating expenses		446,965
Operating Loss from Discontinued Operations		(390,414)
Other Expense:
Interest expense, net		(232,056)
Net Loss from Discontinued Operations		(622,470)
Other Comprehensive Loss Net of Tax:
Foreign currency translation adjustments		(1,275)
Comprehensive Loss from Discontinued Operations		$ (623,745)

XML 35 R25.htm IDEA: XBRL DOCUMENT

Note 5 - Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 25, 2016	Mar. 31, 2016	Dec. 31, 2015
Prepaid expenses - related party		$ 4,250	$ 17,000
Stephen Keaveney [Member]
Professional fees per month paid		10,000
Accrued Professional fees		16,000
Shareholder [Member]
Professional fees per month paid		10,000
Accrued Professional fees		$ 17,250
William L. Ross and Jeffrey Cosman [Member]
Shares purchased	100,000

XML 36 R26.htm IDEA: XBRL DOCUMENT

Note 6 - Debt (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
Note 6 - Debt (Details Narrative) - USD ($)	Mar. 18, 2016	Mar. 31, 2016	Dec. 31, 2015
Convertible Promissory Note [Member]
Convertible promissory note principal amount	$ 60,000
Convertible Debentures, Face Value	$ 16,364
Restricted common shares awarded	15,000
Interest rate	12.00%
Maturity date	Sep. 16, 2016
Debt instrument conversion price	$ 1.00
Convertible Debentures, Carrying Value		$ 29,598
Accrued Interest		260
Interest expense related to the Debenture		260
Debt discount amortization related to the Convertible Note	$ 16,364	2,325
Obligated to pay monthly installments	$ 1,000
August 2014 Convertible Debentures (Series C) [Member]
Convertible Debentures, Face Value			$ 100,000
Interest rate			10.00%
Maturity date			Oct. 31, 2015
Debt instrument conversion price			$ 20.20
Warrants to purchase of common stock			4,950
Warrants to purchase of common stock exercise price			$ 20.20
Warrants to purchase of common stock term			5 years
Convertible Debentures, Carrying Value		110,833	$ 110,833
Accrued Interest		16,625
Interest expense related to the Debenture		$ 3,288
November 2014 Convertible Debentures (Series D) [Member]
Convertible Debentures, Face Value			$ 10,000
Interest rate			12.00%
Maturity date			Oct. 31, 2015
Debt instrument conversion price			$ 16.67
Warrants to purchase of common stock			495
Warrants to purchase of common stock exercise price			$ 20.20
Warrants to purchase of common stock term			5 years
Convertible Debentures, Carrying Value		$ 11,334	$ 11,334
Accrued Interest		1,927
Interest expense related to the Debenture		$ 346

XML 37 R27.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Deficit (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Gross proceeds from sale of common stock	$ 60,000
Gross proceeds from sale of common stock shares	120,000
Common stock shares issued price per share	$ 0.50
Securities issuance costs commissions paid to broker-dealers	$ 6,000
Conversion of six-month convertible promissory note to common stock	15,000
Conversion of six-month convertible promissory note common stock, value	$ 16,363
Gross proceeds from convertible note payable	60,000
Debt beneficial conversion feature for convertible note payable	$ 16,364
Restricted Stock [Member]
Common stock shares issued for services rendered	300,000
Restricted Stock [Member] \| Minimum [Member]
Common stock shares issued price per share	$ 0.90
Restricted Stock [Member] \| Maximum [Member]
Common stock shares issued price per share	1.45
Restricted Stock [Member] \| Board Member [Member]
Common stock shares issued price per share	$ 1.45
Common stock shares issued for services rendered	200,000

XML 38 R28.htm IDEA: XBRL DOCUMENT

Note 8 - Stock-Based Compensation (Details)	3 Months Ended
Note 8 - Stock-Based Compensation (Details)	Mar. 31, 2016 USD ($) $ / shares shares
Note 8 - Stock-Based Compensation
Options Outstanding \| shares	67,879
Option Granted \| shares
Option Cancelled \| shares
Options Outstanding \| shares	67,879
Options exercisable at End \| shares	66,635
Outstanding at Beginning, Weighted-Average Exercise Price \| $ / shares	$ 21.40
Weighted- Average Exercise Price, Granted \| $ / shares
Weighted- Average Exercise Price, Cancelled \| $ / shares
Outstanding at Ending, Weighted-Average Exercise Price \| $ / shares	$ 21.40
Weighted- Average exercisable at End \| $ / shares	$ 21.78
Weighted- Average Remaining Contractual Term, Beginning balance	7 years 2 months 1 day
Weighted- Average Remaining Contractual Term, Ending Balance	6 years 11 months 1 day
Weighted- Average Remaining Contractual Term, exercisable at End	6 years 9 months 26 days
Aggregate Intrinsic Value \| $
Aggregate Intrinsic Value, exercisable at End \| $

XML 39 R29.htm IDEA: XBRL DOCUMENT

Note 8 - Stock-Based Compensation (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 31, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Reverse spilit	1 for 101
Options Outstanding		67,879		67,879
Unrecognized stock compensation expense		$ 780
Unrecognized stock compensation expense recognition period		1 year
Share based compensation		$ 12,284
Chief Executive Officer [Member]
Options Outstanding					24,753
2009 Employee, Director and Consultant Stock Option Plan (the " 2009 Plan")
Reverse spilit				1 for 101
Authorized option pool				18,152
Stock option description				Stock options typically vest over a three-year period and have a life of ten years from the date granted.
Shares available for awards		3,610
2012 Employee, Director and Consultant Stock Option Plan (the "2012 Plan")
Reverse spilit				1 for 101
Authorized option pool				74,257
Stock option description				Stock options typically vest over a three year period and have a life of ten years from the date granted.
Shares available for awards		45,673

XML 40 R30.htm IDEA: XBRL DOCUMENT

Note 9 - Warrants to Purchase Common Stock (Details)	3 Months Ended
Note 9 - Warrants to Purchase Common Stock (Details)	Mar. 31, 2016 $ / shares shares
Options Outstanding \| shares	67,879
Options Granted \| shares
Options Expired \| shares
Options Outstanding \| shares	67,879
Options exercisable at End \| shares	66,635
Outstanding at Beginning, Weighted-Average Exercise Price \| $ / shares	$ 21.40
Weighted- Average Exercise Price, Granted \| $ / shares
Weighted- Average Exercise Price, Expired \| $ / shares
Outstanding at Ending, Weighted-Average Exercise Price \| $ / shares	$ 21.40
Weighted- Average exercisable at End \| $ / shares	$ 21.78
Weighted- Average Remaining Contractual Term, Beginning balance	7 years 2 months 1 day
Weighted- Average Remaining Contractual Term, Ending Balance	6 years 11 months 1 day
Weighted- Average Remaining Contractual Term, exercisable at End	6 years 9 months 26 days
Warrant [Member]
Options Outstanding \| shares	78,462
Options Granted \| shares
Options Expired \| shares	2,475
Options Outstanding \| shares	75,987
Options exercisable at End \| shares	75,987
Outstanding at Beginning, Weighted-Average Exercise Price \| $ / shares	$ 29.55
Weighted- Average Exercise Price, Granted \| $ / shares
Weighted- Average Exercise Price, Expired \| $ / shares	$ 50.50
Outstanding at Ending, Weighted-Average Exercise Price \| $ / shares	30.51
Weighted- Average exercisable at End \| $ / shares	$ 30.51
Weighted- Average Remaining Contractual Term, Beginning balance	3 years 5 months 5 days
Weighted- Average Remaining Contractual Term, Ending Balance	3 years 3 months 15 days
Weighted- Average Remaining Contractual Term, exercisable at End	3 years 3 months 15 days

XML 41 R31.htm IDEA: XBRL DOCUMENT

Note 9 - Warrants to Purchase Common Stock (Details Narrative)	1 Months Ended	3 Months Ended
	Jan. 31, 2016	Mar. 31, 2016
Reverse spilit	1 for 101
Warrant [Member]
Reverse spilit		1 for 101
Warrants expires through		Dec. 31, 2019

XML 42 R32.htm IDEA: XBRL DOCUMENT

Note 10 - Commitments and Contingencies (Details Narrative)	1 Months Ended
	Dec. 16, 2015 USD ($)
Note 10 - Commitments and Contingencies
Damages sought	$ 177,270
Interest rate	12.00%

XML 43 R33.htm IDEA: XBRL DOCUMENT

Note 11 - Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)		1 Months Ended
	Apr. 11, 2016	Apr. 29, 2016	Apr. 04, 2016
Agreement purchase consideration			$ 450,000
Debt instrument conversion price			$ 1.25
Intellectual Properties [Member]
Debt instrument conversion price		$ 1.25
P3 Compounding of Georgia, LLC [Member]
Agreement purchase consideration		$ 1,000,000
Debt instrument conversion price		$ 1.25
Convertible debt		$ 425,000
Interest rate		6.00%
Short term note		$ 75,000
Maturity date		Jun. 16, 2016
P3 Compounding of Georgia, LLC [Member] \| Intellectual Properties [Member]
Debt instrument conversion price		$ 1.25
Convertible debt		$ 425,000
Interest rate		6.00%
Short term note		$ 75,000
Maturity date		Jun. 16, 2016
Mr. James Driscoll [Member]
Restricted common stock issued as compensation	100,000
Mr. Casey Gaetano [Member] \| P3 Compounding of Georgia, LLC [Member]
Restricted common stock issued as compensation		125,000
Officers compensation		$ 125,000

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( !!?M$B.CI^1L0$ (6 3 6T-O;G1E;G1?5'EP97-= M+GAM;,V8RV[",!!%?P5E6Q%CIZ4/ 9O2;8O4_H";3(A%'%NV"?#WM0-4;916 MT!)I-GEPQW-O,LY9,'G;:;"#K2PK.XT*Y_0#(38M0'(;*PV55W)E)'?^UBR) MYNF*+X&PT6A,4E4YJ-S0A1[1;/)2@S$B@\'C7@B]IQ'7NA0I=T)5I*ZR5M>A MRG.10J;2M?1+8N>MXM2[% *P( L !?.0Q(OW[CMB PD.MQ-*O>X^NO ZIK XTHO8<4M?'5$Q^ M#*G*_=ITJK$"2+8CCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7.U49V M[M,41Y26M#;3"&>6X9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//>997'L=V M+YRO+0O]C^AY%.!)T:'B1?4C9@,2[2F]@OIZ (4QOCLEFI2"(S>C@KN_V/P" M4$L#!!0 ( !!?M$BNKFRH?P$ / 4 : >&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'/%V$MJPS 0QO&K!!^@\HSR)LFJFVS;7D X$]LD?B"IM+E] M72^*^]#01>#;V-B&T7]A?@CMVI!OG^3J8MVUH:K[,'MOKFW8#N_W615COS4F M%)4T+CQTO;3#UW/G&Q>'1U^:WA475XKA/%\:/YV3'78_9\^.IWWFCR?*9B_. MEQ+WV5OG+Z$2B<&,-WH8%A@^WWKYS_+=^5P7\M@5KXVT\8\*\[5 9M)!G YB M2)!-!UE(T#P=-(<$+=)!"TC0,AVTA 2MTD$K2- Z';2&!&W201M($.6*C#DF M2<,:HS4I7!/&:U+ )HS8I)!-&+-)09LP:I/"-F'<)@5NPLA-"MV$L9L4O FC M-RMZ,T9O5O1FT%Y;VVQC]&9%;\;HS8K>C-&;%;T9HSC-&;U;T9HS>K.C- M&+U9T9LQ>EM%;XO1VRIZ6XS>5M';@LY*M,,2C-YVHG>HG)?3<_1U6X9[UWP; MKA9-\ [Q=I7[IXQ3U8:)UG%82;<" #["0 $ &1O8U!R;W!S+V%P<"YX;6R]5M]/VS 0_E>L MO(R7DC0!!E6)-%JF3=J@6@L\&^?26#AV9CL5W5^_O'49?E2%((S:KF2\4_.M#(JM>3VE8&8 M^N\=*@1&7@(K-;?;.*A]FJ;*9\FH@!GFBE,J#-1>_XR5STSE!95;O[[]X/+% M/!0K-:<6FJCV@SIZ1C4DF+05?6^L?+YML4_AL+.,RC4D3=^/#W=!K@9T_!SE['!IIPN5Y0KDT\W=C)!IA5^FU,&SMT2HEB;NCF<87U&8\\4P/N M>.UMJ.946H\8_@>OH5>GK:W5613&ZOA)Z1>3 5@S]??&ZMCT;9[Y61Q%E0>> MVI[^OK/XC;96W\ZRXE: N4\75-O_1$75TXZ(*/(:W>]"$"H3NO\EWPM.'QVE5C%7C(E$OQ-^(3^V#'O@%SN(*,;%+&;2XX[8%"2 MQS%7B'FB&@M&25E%%J5F&:+)K&. 8(P>,ZM6P)3$35S+'5@QM4$GPW\+MWB MW&X^ZL]9&/3G+!SW[R<,^PLX/+SXG1R$9_T%'!Y>_): R&ULS9--3\,P#(;_"NJ]2]MI.U1=#X X,0F)(1"WD'A;6/.A MQ%/7?T_F=2T#+KMQJVN_CU_'225<*:R')V\=>%00;@ZZ,:$4;I%L$5W)6!!; MT#Q,8H6)R;7UFF,,_88Y+G9\ ZS(LCG3@%QRY.P(3-U 3.I*BE)XX&A]CY=B MP+N];P@F!8,&-!@,+)_D+*E?S,[8UE1LU-=5=-SP@$LKU5J!O.W&LM^IV!G! MZW"2@QS:T]\_/5"&)7WE(:BAJFW;23NENCAPSMZ6C\]T-JDR ;D1$%5!E=@Y M6"3GSJ_3N_O50U(763Y/LUE:9*L\+V?SLIB^'R>[\#<:UOT0_];QV2!M%Q4V M<.5N22-IN?1)( E!>.5067,5CC#?Q 0+^X]/$'@]J!?29=M!UUHO0TWW:XR. M+R>N;&-]=TK]B"Y>5?T%4$L#!!0 ( !!?M$B97)PC$ 8 )PG 3 M>&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;; MM)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+H MAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J M9S]6:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X M.+;+THMP' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J- M6T_3:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E M0-,@ %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 % M#@ WQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU] M.LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1& M)$6?R"VZY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CW MJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?" MJ_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4 MOK4F.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J=W#HX MGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZA MAIC/PT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%; MQ@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54= MSU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ M(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#; M.MX#7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE M9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPY MC0IO0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$ M% @ $%^T2"L5U!$NEJD^>5ZB@IS?9(+R9#26UEX M=24QRFH3Q*BW\OVUQQ#A, YYPS9,U2 5#5<17 T0'N(7]N 2 L?Q)8M@L+Z&WNFD2_\XKSX[H%X;:J^O(0YSP>>E M&" .ZR>P0U3[!\8]%51(H'2OM :+<,2P\[A#E"22&#!'C-#.P2L#V/;V?HQP M(6UNE^$PS](?,\DBB:#?_TY/EXSL=C'E$4KGY6D@#BND%)9\HS>@M[==I8OC M@F,GTOH]XUU(U 6KZTF 773>1,@,RR%S /=0'%*<*QT@25&:58G*2!=*"::- MC*!"<$0-Y3ZB-S1MBBE],)?Y1S[C;G/@?,PS]B$P*O:F;D1OCM? -M6;LCGN M*:W_(E[0YD,"'8VJBG:?*2DXPTZL@S:BWSU''QRACT.T9P6ED.1)^YN+D&H M2PAV6"J23I%?$E5;W*K^!GMM?DSA2TO^FYK>OFNC>%_W5[_FORZ;.Q?T-X MH.>$1W'?L 3+C9W-?R[LZN.Y*C/OGK.5MCY7:5"U'2@B.-K?<$8:=F,5C%]=\6]02P,$% @ $%^T2#UV;4** P M^@L \ !X;"]W;W)K8F]O:RYX;6R5EDU3VS 00/^*QI=RH;'E)$"&<(#0 MEIF6,@V%LV(K9 =9V]:J?'>VMA&>!S:AY%9KZ&2"U-UC=1^Q/-\.K)2 M"0]&NPVT+GNEN?^AN=9*4;N-E+Y1/:P1H+.S4S=;@Y)WTCH$,]&VUZ*1\^RG MRI@2SE_6X&4]S\8X-,]R<,%V[7D'*@PF^20;!=AVJ3>65::6/>QV ^[^]4;& M:KD6G?*W.-GM=^=9P<><3WM&>.P.Y+.CP'"!B78;GQR08T-/ KS!M';F.>/QD+OXSV0BTK:Y2*;X4; M\27\@OMS!>?HH1H\Z,7J6\C$/)OF"'P"!RM0X%_F63Q7,JQD],]28OC_GC$= M@[--,1.Z9I?:(X5=Z3YY&)HP!WSXJHX?MC/ $WM5%WVH*.@"Q3 *:HQ%S;N0!7X7Z!@9 Y-3)/H":(^A8J%P;Z1EC4^]8*[7 O4]1 [AUV1]0T!GPU M>)'*7.RP.;YX%);C3?6X,:K&FO,.,1A@&)"HS<4.G2/I>$LZ/!M1@N76X M5RF*^ESL$#JB3A!U+RP& S>6-^RFL]4&H>R"HJC1Q0ZE>Q-S9.%4&O"AEKB8 MLHN0+XJB3A=)J8LHX\K)'UTH2Y=/ 4@QU.AB7Z6+8XJB3A<4-:C:*=%3!8#3LLVIZ3QE>BKL M?$Q1U'2>,CU5 C@MW9R:SE.F;TL .UA(+T Y=AV2@'T!15'3>TEM;WA.H2 MQE^PIYUGH?'$'K-3Z@*O?=6?C8CM64_>=JQGOP%02P,$% @ $%^T2/,G MT^IF @ OP@ !@ !X;"]W;W)KU#I=4^M,\.. $M8&H[8?OWM0UAJ3TT#\&7<^9X[!F/ MLX'Q=U%1*KV/MNG$P:^D[/=!((J*MD2\L)YV:N;*>$NDZO);('I.26E(;1/@ M,$R#EM2=GV=F[)7G&;O+IN[H*_?$O6T)_W.B#1L./O*? V_UK9)Z(,BS8.:5 M=4L[4;/.X_1Z\(]H?T:IAAC$SYH.8M'V].(OC+WKSO?RX(=Z#;2AA=0FB/H\ MZ)DVC;:DE']/1C\U-7'9?EK_:MQ5R[\00<^L^567LE*K#7VOI%=R;^0;&[[1 MR8=$&RQ8(\R_5]R%9.V3XGLM^1B_=6>^PS@3HXD&$_!$P#,!I_\E1!,AF@DH M-IZ.*S-^?2&2Y!EG@\?'P^B)/G.TC]3.%7K0;)294YX)-?K(PRQX:#,3XC0B M\ *!9D2@;,\"&!(X88>._Q4XNX@(%HA #R)#CQ;T&*;'(#TV]'A!3ZP-\'**5"UT)J)Q6 63EOM)*XR+5@ M'SF$65,!L_>(L&MA9ZNX&!RNJ, IC"+7 K)5 Q>48$S';F)C"/K+IHPRUQ$ M. GU;T4+3GKD9CVV VW")$O,6J3!28_S>F;*]&)UK]1&;>O,)S[.>W.@/PF]U)[P+DZIJF=IR94Q2M9CP13E;J=?$ MW&GH5>KF1K7Y6%_'CF3]\[DPOUGROU!+ P04 " 07[1("H[]=D0# _ M#@ & 'AL+W=OS1EUCS8DZGZ M75Z:JLEM%=1FOPP_P^.&\2[2)W[FYM),]H,._L7:U^[@^VX9QAV#*!C ?<*HH&L']>7K,U6B]I>@GJX&:>LN^?PR-V5VW8G^PO5_^=&UKBS;RNF M%]%;U\X860\1-HW<)C9$(KE&(M?_%8*1$*ROY]/ZE*[G9#WOZ\6DGL?>((:( M[B-5'P&=). -!*=8 HFD603)(C"+U\MZB*@I"W"1>"Q$0XP&D22(Q/7< Y$( M1##I7;F-)*Y<',)"29\'\"S@G,W<;: U!PSQ"-]38V;*PU*9 M^G(@FIJS ]#.!"Q-X8MJS-S ,'LO=S"T)[5' (A5H%902S[B8O@A'&B('6LF9%R:C5KW7X]?-\, M!ZT]?7RN7;\95W\!4$L#!!0 ( !!?M$@Z:!&M(0( (\' 8 >&PO M=V]R:W-H965T&ULC97+CILP%(9?!?$ L;F3B" UJ4;MHM)H M%NW:(4Y 8S!C.V'Z]K4-H6 \2;*(;_]_SG? V%E'V3LO,1;.9TT:OG5+(=H- M +PH<8WXBK:XD2LGRFHDY)"= 6\91D=MJ@GP(8Q!C:K&S3,]]\KRC%X$J1K\ MRAQ^J6O$_NXPH=W6]=S;Q%MU+H6: 'D&1M^QJG'#*]HX#)^V[C=OL_>@DFC% M[PIW?-)W%/R!TG"/!B^\:P@&0V 80$^FZ_J.!,HS1CN']2^C1>J=>YM M/KE"3>H'I==D95S.7O/(S\!5Q1DDNU[B3R2&8F]1I*,$R/PCA&^%\+4_F$($ M=G]@]0?:'T[]H5%$+TFUI-$2N(*>4<<#T8PDM)*$2Y+((.DE\22)!_N?0?.$ M<$8468FB)5%L$$6+1";*/<6,(;8RQ$N&Q&"('S+<4\P8$BM#LF1(#8;DF3WR M0#0C2:TDZ9)D;9"DBUHC:-\DSRAG3&LKTWK!%!N9=NOE=O1#&Y)%Z"5Q]"61 M.F9M)Q-<,GGFT02?A;(I[51@ ?G_P!02P,$% @ $%^T2!\=%8FT256UATJK/;1G-G$2M(!3<#;;?U]C" N>@4US"&#>&3]C[%>: MY"JKU_HDA'+>B[RL5^Y)J?.#Y]6[DRC2>B'/HM1O#K(J4J4?JZ-7GRN1[DU0 MD7O4]V.O2+/272=F[*E:)_*B\JP43Y537XHBK?YN1"ZO*Y>XMX'G['A2S8"W M3KP^;I\5HJPS63J5.*S<1_*PI5$C,8I?F;C6@WNG@7^1\K5Y^+%?N7[#('*Q M4TV*5%_>Q%;D>9-)S_RG2_HQ9Q,XO+]E_V;*U?@O:2VV,O^=[=5)T_JNLQ>' M])*K9WG]+KH:#.%.YK7Y=W:76LGB%N(Z1?K>7K/27*_M&^YW87@ [0)H']#/ M@P<$74#P$1":2ELR4]?75*7KI))7IVH_QCEMOCEY"/3*[9I!LU#FG:ZLUJ-O MZY@FWEN3IY-L6@D=2$BO\'3R?@:*S;"A(-R:8 L5<8#/$* U!"8^&,:'>'R( MQH:N+/8)!FA-LP,-4D#&YF)( PH0T3@&VCUX9'G-DX,-DD#NZ-!-H:L\T1T8"S-*\9 MD^#^2*"U,=L@.\T="W._3Q+<*$D,/(JQB0RXR1$&"^)V05 #EY;!HF-*PX'9 MC'%PSR30[IAMFH@&XG!X4@@=;)HQ#&Z=!#H>M[T3T4"8)79L Q9.X%#ET/ZX[:2=A@^G\A<^ M\T<_8@/>;ZP4-U8*O9#;QHIHP);J-"-^LB!3"X7;*H5VR&U;[33_NU!(U P> M[K44VB.WO;;3#+H&DI1'4TS5SM[.2E5$U_,!CM M&\9'VC0]UOA&-Y)MV_>19IV&PO=V]R:W-H965T&ULC9=+_"L,] M00))B(SMF1K<:0^=R>30GHDMVTP N2#'Z;>O!/B!5CBYF-=O'_]=HQ6SDVS> MVKT0RONHRKJ=^WNE#D]!T*[WHLK;1WD0M7ZRE4V5*WW9[(+VT(A\TQE591 B MQ((J+VI_,>ON/3>+F3RJLJC%<^.UQZK*FW]+48QO#V_.S]>R=7I_^:MR*5Y9]BH_8Z6^1[&['-CZ5Z MD:Z9KU^J[[PL>SX)WXV= ECT2WB)\C*0.)!DC&402-$96#@1?D$#+ MN&@)G5K"SI[6EAZ).Z3N$(QC1JU,4HA%";;JDD'H@1$<4FK)84 ;LNO\!7"4$7%F1&!&Q,J(P&J'=C8I =G0D-M4!J-% M5F]7,!HEDYJH4Q.%FJQN+BDLGM8T%88YPS 8AEEA&!0#&IDR6#H>4E [& [4 MSN4IIE.J8J>J&*JREY(8AD'3Q>/.,!R&L9:C)8?_._"*<]A'%F+KG^YA./@P MLB>? X+"/FY5@'?@*V:<5W&P4#_E. M_,J;75&WWJM4>L_9[0RW4BJAO:)'/?OV^FOC&PO=V]R:W-H M965T&ULC9A=;YLP%(;_"LI]AWW,5ZHT4I-IVBXF5;O8KFGB M)&B ,R!-]^]G/IJ"STNU7C1@SGG]'@R/;5974_VN3UHWWFN1E_7#XM0TYWO? MKWM6U/57KE;DT M>5;JI\JK+T615G\W.C?7AX5%H_R M?JM$&])%_,STM1X=>ZWY9V-^MR??]@\+T7K0N=XUK41J?U[T5N=YJV1[_C.( MOO?9)HZ/W]2_=.5:^\]IK;7A_22][\,->O>J@A; 5W)J^[ M_][N4C>F>$M9>$7ZVO]F9?=[[:_$T9"&$VA(H%O"K1^.(D@4X2[D0*QTD?$XV&1Y(_^G(&!A+R MYE$2-^'>W2%F7-"=[2=(W(* UEQ!F$U2<07ENE',C21[>UTS0&K.#.:5G=1=/Q\B;?##Z7@7Q%$R9P>CCSBO)+D@!D'<#NS"FT=:F M^&1?E9-.][>37!^:]C"VQU6_N^]/&G-^^UAQ^V*R_@=02P,$% @ $%^T M2 0 L0, !@ !X;"]W;W)KMC#O2SOO^P)BK.M#"W6 /)MPT:+7PP;0M<[T%42>05HQG MV1W30AI:%LGW;,L"!Z^D@6=+W*"UL+].H' \TAV].EYDV_GH8&7!%EPM-1@G MT1 +S9'>[PZG?8Q( =\EC&YU)E'[&?$U&E_K(\VB!%!0^<@@PG:!!U J$H7$ M/V?.]Y01N#Y?V1]3M4']63AX0/5#UKX+8C-*:FC$H/P+CD\PEW ;"2M4+JVD M&IQ'?850HL7;M$N3]G&ZR?,9M@W@,X O@,]9$CXE2C*_""_*PN)([-3:7L07 MW!UX:$05G:GN=!>$NN"]E+L\*]@E$LTQIRF&KV.6"!;8EQ1\*\6)_P7GV_!\ M4V&>X/D_%'X@V&\2[!/!_K\E;L7\621;]52#;=/H.%+A8-*@KKS+=-[S]";O MX671BQ:^"=M*X\@9?7C9U/\&T4.0DMW<4M*%_[,8"AH?CY_"V4XC-1D>^^L' M67YI^1M02P,$% @ $%^T2&!A"EN? 0 L0, !@ !X;"]W;W)KPUW%;MQ=@AGEOW@Q#,:)]<1V )V]:&7>BG??]D3%7=:"%N\,> M3+AIT&KA@VE;YGH+HDX@K1C/L@],"VEH623?DRT+'+R2!IXL<8/6POX\@\+Q M1'?TYGB6;>>C@Y4%6W"UU&"<1$,L-"=ZOSN>]S$B!7R7,+K5F43M%\27:'RM M3S2+$D!!Y2.#"-L5'D"I2!02O\Z<[RDC<'V^L7].U0;U%^'@ =4/6?LNB,TH MJ:$1@_+/.'Z!N81#)*Q0N;22:G >]0U"B19OTRY-VL?IYL!GV#: SP"^ #YE M2?B4*,E\%%Z4A<61V*FUO8@ON#ORT(@J.E/=Z2X(=<%[+7X/D_%/Y&L-\DV">"_7]+W(K)_TC"5CW5 M8-LT.HY4.)@TJ"OO,IWWZ1'9>WA9]**%;\*VTCAR01]>-O6_0?00I&1W!TJZ M\'\60T'CX_%C.-MII";#8W_[(,LO+7\!4$L#!!0 ( !!?M$C;5QP+GP$ M +$# 8 >&PO=V]R:W-H965T&UL?5/!;MP@$/T5Q <$ M+^MMJI774C95U1XJ13FT9]8>VRC N(#7Z=\7L-=Q4[<78(9Y;]X,0S&B?7$= M@">O6AEWHIWW_9$Q5W6@A;O#'DRX:=!JX8-I6^9Z"Z).(*T8S[(/3 MI:%DD MWY,M"QR\D@:>+'&#UL+^.H/"\41W].9XEFWGHX.5!5MPM=1@G$1#+#0G^K [ MGO,8D0*^2QC=ZDRB]@OB2S2^UB>:10F@H/*1083M"H^@5"0*B7_.G&\I(W!] MOK%_3M4&]1?AX!'5#UG[+HC-**FA$8/RSSA^@;F$0R2L4+FTDFIP'O4-0HD6 MK],N3=K'Z2:_GV'; #X#^ +XF"7A4Z(D\Y/PHBPLCL1.K>U%?,'=D8=&5-&9 MZDYW0:@+WFNYV^<%NT:B.>8\Q?!US!+! ON2@F^E./._X'P;OM]4N$_P_3\4 M_D&0;Q+DB2#_;XE;,8=W2=BJIQILFT;'D0H'DP9UY5VF\X&G-WD++XM>M/!- MV%8:1R[HP\NF_C>('H*4[.Y 21?^SV(H:'P\WH>SG49J,CSVMP^R_-+R-U!+ M P04 " 07[1(!'8XX)\! "Q P &0 'AL+W=OPUW%;MQ=@AGEOW@Q#,:)]=1V )V]:&7>BG??]D3%7=:"%N\,>3+AIT&KA M@VE;YGH+HDX@K1C/L@/30AI:%LGW;,L"!Z^D@6=+W*"UL#_/H' \T1V].5YD MV_GH8&7!%EPM-1@GT1 +S8D^[H[G/$:D@&\21K\H(7)]O[)]2M4']13AX0O5=UKX+8C-*:FC$H/P+ MCI]A+N$^$E:H7%I)-3B/^@:A1(NW:9-TDQ]FV#: SP"^ #YD2?B4*,G\ M*+PH"XLCL5-K>Q%?<'?DH1%5=*:ZTUT0ZH+W6N[VAX)=(]$<K*NTSG(T]O\AY>%KUHX:NPK32.7-"'ETW];Q ]!"G9W3TE7?@_BZ&@ M\?'X$,YV&JG)\-C?/LCR2\M?4$L#!!0 ( !!?M$AK_?PRH $ +$# 9 M >&PO=V]R:W-H965TI.G* M:RF;JFH/E:(A@9<$67"TU&"?1$ O-D3[L#J=]C$@! MWR6,;G4F4?L9\24:7^LCS:($4%#YR"#"=H%'4"H2A<0_9\ZWE!&X/E_9/Z=J M@_JSL?1?$9I34T(A!^6<%$6%D=BI];V(K[@[L!#(ZKH3'6GNR#4 M!>^EW.7W!;M$HCGF-,7P=M'"-V%;:1PY MHP\OF_K?('H(4K*;6TJZ\'\60T'CX_%#.-MII";#8W_](,LO+7\#4$L#!!0 M ( !!?M$B*)2&AG0$ +$# 9 >&PO=V]R:W-H965TA@ M9<$67"TU&"?1$ O-D=[O#J<\1J2 [Q)&MSJ3J/V,^!J-K_619E$"**A\9!!A MN\ #*!6)0N*?,^=[R@AE(7% MD=BIM;V(+[@[\-"(*CI3W>DN"'7!>REW>5:P2R2:8TY3#%_'+!$LL"\I^%:* M$_\+SK?A^TV%^P3?_T/A!X)\DR!/!/E_2]R*^;-(MNJI!MNFT7&DPL&D05UY ME^F\Y^E-WL/+HA&PO M=V]R:W-H965T]^;->%Q,:%YM!^#(FU:]/=+.N>' MF*TZT,+>X "]OVG0:.&\:5IF!P.BCB"M&$^2.Z:%[&E91-^S*0L)%MYX*#E05;<;74T%N)/3'0'.E]>CCE(2(&?)0*E Y!/_7#C?4P;@]GQE?XS5>O5G8>$! MU0]9N\Z+32BIH1&CN"^$55PQKKCG1=JO?=2ICDO MV"40+3&G.89O8]8(YMG7%'POQ8G_!>?[\&Q781;AV3\4?B#(=PGR2)#_M\2] MF.R/)&S34PVFC:-C285C'P=UXUVG\Y['-WD/+XM!M/!-F%;VEIS1^9>-_6\0 M'7@IR6OP%02P,$% @ $%^T M2'CY%/:? 0 L0, !D !X;"]W;W)K&UL?5/! M;MP@$/T5Q <$+^MMJY774C91U1XJ13FT9]8>VRC .(#7Z=\7L-=Q6[<78(9Y M;]X,0S&B?7$=@"=O6AEWHIWW_9$Q5W6@A;O#'DRX:=!JX8-I6^9Z"Z).(*T8 MS[(/3 MI:%DDWY,M"QR\D@:>+'&#UL+^/(/"\41W].9XEFWGHX.5!5MPM=1@ MG$1#+#0G>K\[GO,8D0*^2QC=ZDRB]@OB2S2^UB>:10F@H/*1083M"@^@5"0* MB5]GSO>4$;@^W]@_IVJ#^HMP\(#JAZQ]%\1FE-30B$'Y9QR_P%S"(1)6J%Q: M234XC_H&H42+MVF7)NWC=+//9]@V@,\ O@ ^94GXE"C)?!1>E(7%D=BIM;V( M+[@[\M"(*CI3W>DN"'7!>RUW>5ZP:R2:8\Y3#%_'+!$LL"\I^%:*,_\+SK?A M^TV%^P3?_T/A;P3Y)D&>"/+_EK@5<_@C"5OU5(-MT^@X4N%@TJ"NO,MTWO/T M)N_A9=&+%KX)VTKCR 5]>-G4_P;10Y"2W1THZ<+_60P%C8_'C^%LIY&:#(_] M[8,LO[3\!5!+ P04 " 07[1(A.#Z[9\! "Q P &0 'AL+W=OMC#O2SOO^P)BK.M#" MW6 /)MPT:+7PP;0M<[T%42>05HQGV1W30AI:%LGW;,L"!Z^D@6=+W*"UL#]/ MH' \TAV].EYDV_GH8&7!%EPM-1@GT1 +S9$^[ ZG/$:D@.\21K4?V0M>^" MV(R2&AHQ*/^"XQ>82[B-A!4JEU92#)]VJ5)^SC=Y/L9M@W@,X O M@$]9$CXE2C(_"R_*PN)([-3:7L07W!UX:$05G:GN=!>$NN"]E+O\KF"72#3' MG*88OHY9(EA@7U+PK10G_A><;\/WFPKW";[_A\+?"/)-@CP1Y/\M<2OF_H\D M;-53#;9-H^-(A8-)@[KR+M/YP-.;?(2712]:^"9L*XTC9_3A95/_&T0/04IV MA[.=1FHR//;7#[+\TO(74$L#!!0 ( !!?M$B0 MGP$ +$# 9 >&PO=V]R:W-H965T S@"^ NP1@4Z(D\[/PHBPLCL1.K>U%?,'=@8=& M5-&9ZDYW0:@+WDNYR^\*=HE$<\QIBN'KF"6"!?8E!=]*<>)_P?DV?+^I<)_@ M^W\H_(T@WR3($T'^WQ*W8C[]D82M>JK!MFET'*EP,&E05]YE.N]Y>I/W\++H M10O?A&VE<>2,/KQLZG^#Z"%(R6YN*>G"_UD,!8V/QX_A;*>1F@R/_?6#++^T M_ 502P,$% @ $%^T2.$IM0R> 0 L0, !D !X;"]W;W)K&UL?5/!;MP@$/T5Q <$+[N;1BNOI6RJ*#E4BG)HSZP]ME& M<0&OT[\O8*_CIFXOP SSWKP9AGQ ^^9: $_>M3+N2%OONP-CKFQ!"W>#'9AP M4Z/5P@?3-LQU%D250%HQGF6W3 MI:)$GWXLM+'&]UL+^.H'"X4@W M].IXE4WKHX,5.9MQE=1@G$1#+-1'>K\YG'8Q(@5\ES"XQ9E$[6?$MV@\5T>: M10F@H/21083M @^@5"0*B7].G!\I(W!YOK(_IFJ#^K-P\(#JAZQ\&\1FE%10 MBU[Y5QR>8"IA'PE+5"ZMI.R=1WV%4*+%^[A+D_9AO.%W$VP=P"< GP%W61(^ M)DHROPHOBMSB0.S8VD[$%]P<>&A$&9VI[G07A+K@O12;?9:S2R2:8DYC#%_& MS!$LL,\I^%J*$_\+SM?AVU6%VP3?_D/A'P2[58)=(MC]M\2UF,]%LD5/-=@F MC8XC)?8F#>K".T_G/4]O\A%>Y)UHX)NPC32.G-&'ETW]KQ$]!"G9S9Z2-OR? MV5!0^WC\$LYV'*G1\-A=/\C\2XO?4$L#!!0 ( !!?M$BF07=;R@$ . $ M 9 >&PO=V]R:W-H965T(#% =' M;2>.2:>;9O=BDZ87[36CQY\4Q *.W;$WE77;*706 MVC2"NZZ5$!I,*N&-.=7&/#?+@D&E[30U&PO=V]R:W-H965T*D4YM&?6'MLHP#B U^G?%[#7 M<5-?@!GFO7DS#,6(]M5U )Z\:V7]T?&7-6!%NX.>S#AID&KA0^F;9GK M+8@Z@;1B/,L.3 MI:%DDW[,M"QR\D@:>+7&#UL+^.8/"\41S>G.\R+;ST<'* M@BVX6FHP3J(A%IH3?$3U6]:^"V(S2FIHQ*#\"X[?82[A M/A)6J%Q:234XC_H&H42+]VF7)NWC='/@,VP;P&< 7P!?LR1\2I1D/@DORL+B M2.S4VE[$%\R//#2BBLY4=[H+0EWP7LO\D!7L&HGFF/,4P]9?I?$B/R#["RZ(7+?P4MI7&D0OZ\+*I_PVBAR EN[NGI O_9S$4-#X> MOX2SG49J,CSVMP^R_-+R+U!+ P04 " 07[1(GF'B%Z(! "Q P &0 M 'AL+W=OAQ=,#YEO1!6YXYX5:[[V4 MZ>VN8)= -,>^;.91FHR'/;7#[+\TO(34$L#!!0 M ( !!?M$C>\%;"H@$ +$# 9 >&PO=V]R:W-H965TVC.QQS8J,"[@N/W[ G9< M;]<78(9Y;]X,0SZ@>;,M@",?2FI[I*USW8$Q6[:@N+W!#K2_J=$H[KQI&F8[ M [R*("59FB1[IKC0M,BC[\D4.?9."@U/AMA>*6X^3R!Q.-(-O3J>1=.ZX&!% MSF9<)11H*U 3 _61WF\.IRQ$Q( 7 8-=G$G0?D9\"\:?ZDB3( $DE"XP<+]= MX &D#$0^\?O$^9TR )?G*_NO6*U7?^86'E"^BLJU7FQ"204U[Z5[QN$W3"7L M F&)TL:5E+UUJ*X02A3_&'>AXSZ,-[MT@JT#T@F0SH"[) H?$T69C]SQ(C'U#>B#,Y8=[SS0JWW7HK-?I^S2R":8DYC3+J,F2.89Y]3I&LI M3NE_\'0=OEU5N(WP[3)[ME\GR%8)LDB0_5/B[8\2UV+N?B1ABYXJ,$T<'4M* M['4&ULC55=CZ(P%/TKA!\P?-6"!DE& MS6;W89/)/.P^5ZQ"IJ5,6V7VWV];$!7N)"9&VLLYYY[>EMN\$_)#591J[XNS M1JW]2NMV%02JK"@GZD6TM#%OCD)RHLU4G@+52DH.CL19$(Q- M%KDX:U8W]$UZZLPYD?\VE(EN[4?^-?!>GRIM T&1!R/O4'/:J%HTGJ3'M?\: MK79+BW" /S7MU-W8L][W0GS8R:_#V@^M!"#$(V', Q.2@9 \2T # =T(R)6F7XHKQ(YH M4N12=)[L-Z\E]HQ$*V1*7=J@JZQ[9TJA3/121'B9!QUFN.BC!&T0)V@T$W&'"#88$4%$B?6$XZ M,XK3+)V)^4W,!'E^,EU;Q'U!+ P04 M" 07[1(ZM(JQ^0! U!0 &0 'AL+W=O=T58>W5JI[H"0+&I@1-[Q#EJ]4W'!B-)+<4&R M$T!*2V(4!9X7(T::ULTS&WL6><:OBC8M/ M'7ADCXO<]4-X?7=^= B_-I58F M@/(,S;RR8=#*AK>.@.KH?O4/C]@@+.!G [U;G "2HV0/OAMU/Q[I"$NYY/ZDW6KLS\3"2=.?S6EJG6RGNN44)$K52^\ M_P:CA<@(%IQ*^W6*JU2<31378>1]&)O6COVPDR0C;9\0C(1@)OCXOX1P)(2? M)>"1@#]+B$9"M"*@P;NMW -1),\$[QTQW'9'3%/YATC?36&"]BKLGJZ=U-%; M[B=IAFY&:,3<#YA@@0D^(DX[B)7(PQ82AQ\ACUN(GWR9,4C[F,T$NV8"*Q N M!4*\+Q#N"H16 "\$0F]5C &26$@[%2SU5P79HH+43Z-537:TXBC J[+LH+#O M_Z,P>-<7WOJ*5[[PYI3$T[FL[NBTA44Q3I-PE0U:]%]'+O"#B$O32N?,E6YE MVW 5YPJTI'>G6[C6;]B\H% I,TWT7 R_];!0O)L>J?FES/\ 4$L#!!0 ( M !!?M$AJ,!JEI@( $H) 9 >&PO=V]R:W-H965T_8F3H(6<&H[F^V_KVT(2QAS M 6QFYGG],1Z7-R'?U9ES'7RV3:?6X5GKRRJ*U/[,6Z:>Q85WYL]1R)9ITY2G M2%TD9P?GU#81CF,:M:SNPJIT?2^R*L55-W7'7V2@KFW+Y+\M;\1M':+PWO%: MG\[:=D15&8U^A[KEG:I%%TA^7(<;M-JAS)HXB]\UOZG)=V#%OPGQ;AL_#^LP MMAIXP_?:AF#F]<%WO&EL)$/^.P3]8EK'Z?<]^G'08.7X',CB0+X?$C;17YL;UC6E6E5+< MDOQH79-4VHP6D8D^(K /L<7 '3\"=M""$C^!> =!G#^9"B34 M'R#Q!DA<@&0J()UI[$TR9]+U#)33K/!C4B\FA1@ZP_0F=(*A&.'<3Z%>"H64 M;$:A@)+2-%U8U"+X]B"$(ST& S)25F/).M]DA:R%@$2"@'* 103Z2($Y0LL+RI MNT$89E:.%T+XT@+X/U8(-MB9OU;^VUP96^KS!5>6$G M_HO)4]VIX$UH4T!=F3L*H;G1&3^;Q3F;B\W8:/A1V\_,?,N^U/<-+2[WF\MX M?:K^ U!+ P04 " 07[1()BLQ'RX" P!P &0 'AL+W=OTMABQM5WE 3#D0J5 ]76G_B#CL*?Y= M%:*4;EW;*N"$+EA\TO8=^CVL5,*<8JY_K?S"!24WBFT1]-V-5:W'MOL213W- M3/![@C\0!ATS(>@)P;.$L">$=T*H2]-M11?B@ 3*4D9;BW7_7H/4(?$VH2QU MKH*ZLOJ;+ 67T6OF)5'J7%6B'K/K,/X8$[N/F+T!,R &('P03$QTDUI!:0T)_-2G&80Z2!7-=LY70:"6< M6?&2A;VLC E6A@3KR68Z3#3VZ2[ZC(PRT5QF/3T;T5PF6I2)C3*Q06;A@"7& M!,D3Y4C^IQQKH\SZB7*L#:=C?(8>9%33,EU;UR#D+Z18N/F>(44PO?J>N293 MM\ZHWQ!@9]VXN9732ZW?B5%T>!Q>?=VO[O L;= 9?B)VKFIN':F074_WIA.E M J0=]T6>V%(^7\,"PTFH:2SGK&OHW4+0YO8^#8]D]@]02P,$% @ $%^T M2$Z@U#*R P !( !D !X;"]W;W)K&ULE9C= M20?$ME]=FY#U#>X4T4S_/=VEZ95Y6O(PBNS7^,Q MKX;C=7P2I3H,![ .X%L Q7\-$#I O 5$?PT(=4!H./AC5X:!V&9MME[5ZNK5 MX]L[9_TDH?NP&^I=?W,8V>%9-Q1-=_=E36FX\E_ZAK1F,VIXJED&<\T3T,P5 M6Z!(HYO&[[*\I L!!PP,<2'LRR6N($0-A""!A)C MQ$?-G#_^&#JYOL\N; +!LM- M3D?8Z0AV((\P+,BF!9-97V3C@ISU11@79/."R37K, K(9H&%G*T6F;DZL\4X MH'?P8(M$Y "82+0.Y"P12(2#A\,!7H'%;9:E$SG4W#GZ!!C,C @ QD3=ZM% MTXD;II'C#3$& P,PD-DC+7IGCS 9&)"!8M,(B1R_VHS)P(@,UO+#+GFB(!'F ME&% D+ENGA*& P,X6/#5HEE*<>S"$&,Z,*"#A5^VEQ."$\?O"6.&,%A/D*L) MS :VR]["T!,0"6NEN,2HN0F" ",0&JT?\'Z02CIT#((A%*BAR M#1S&@D!8,$DEP)J!A+#&]U^R>4*8'@+1P^24%LTXE;*KYY@> NU&3$P)>P4B MPMCP\2?[YU+6Q^%#1./MU*4:OGM,[MX^=CSRL/]^DZ]7Y^PH/V?U,:\:[UFU MW2Y^V&L?E&IEETMPUW7Z)+/][:*0A[8_77;G]?B!8KQHU?GU>\OMH\_Z#U!+ M P04 " 07[1(7(GKQIL" #P"0 &0 'AL+W=OZ,?X@+I=+[;.I6K/V+E-TJ",3A0ALB%JRCK7IS M8KPA4CWRF(?S?EM;L MOO:1_QAXK\X7J0>"L@@&OV/5T%94K/4X/:W]#5KM4*Y-C,7OBM[%Z-[3R>\9 M^] //X]K/]0YT)H>I Y!U.5&=[2N=21%_ML'?3*UX_C^$?V[*5>EOR>"[EC] MISK*B\HV]+TC/9%K+=_9_0?M:TATP .KA?GW#E 0\. P=VB'J'Z.D0FTIM9J:N;T22LN#L[G'[,3JBOSE:16KF#GK0 M3)1YIRH3:O168I07P4T'ZFVVU@:/;-!@$:CH P)#B"UVW/$K8.=:I!%,B, B M(N,?CPDXG!1A;3)CTUI&J'XP)@8Q,8!!$XRU24<8A.$+)W"E+9C%+$+,$,,D$LW2*06DTM\YR M$),#F'2"R9UJ7M>97?%NI C#F>@F!.DV!'+)IL(-P9KC&=),AT :3D3 NP M&X2!$$Z7P<[,1>&\=!#<"A#0"Z*Y$+#,$:3SJ?YZHU:!8)UC ASZY86*,($JF3Z]*9UB]RA56*()DZJ\W5 M*8966S#:2!O*S^: (;P#N[92;UFCT>$0LS%;_61\JP\W9H-^ABF+CISI+\+/ M52N\/9-JFS>;\8DQ256:JJ?[WD4=OX:'FIZDOLW4/;<'$OL@6?&PO=V]R:W-H965T)!V+V";_\QO;#QC9SWCKZ*D5#IO3=V*O5M*V>T\3Q0E;8C8L(ZV MZLN%\89(U>573W2>9/=N6IH*RK6.IQ>]NX![8XHU1*C^%W17LS:C@[^ MQ-BK[OP\[UU?QT!K6DCM@JC7G3[1NM:>%/GOZ/2=J0WG[8?W[V:Z*OP3$?2) MU7^JLRQ5M+[KG.F%W&KYPOH?=)Q#I!T6K!;FZ10W(5GS,'&=AKP-[ZHU[W[X MDJ#1##; HP&>#(+$!#Z 3)C?B"1YQEGO\&%M.Z)_(=IAM1"%'C3S-M]4H$*- MWG,9\0&$('*PY"T$%H M'(0?(H@6DQPTL=&T1A,G:;*%,1&(B0!,O,#8F@##C!ADQ C63!LS1HC 1G) M)Y8K^!?,!LP4Q6P"S76 &33K#8+19V6(ZR:%$\FU. MZ"\SR1:M_1JTDJ\(P* EQA:M8L"0L !D !X;"]W;W)K M&ULC5;!;J,P$/T5Q <4;,"0B""UI-'N8:6JA]VS MFS@)*N"L[33=OU\;""7VT/82L'DS[WG&,YG\PL6K/#*FO/>F;N7*/RIU6@:! MW!Y90^4=/[%6?]EST5"EE^(0R)-@=-<9-76 PY $#:U:O\B[O2=1Y/RLZJIE M3\*3YZ:AXM\#J_EEY2/_NO%<'8[*; 1%'HQVNZIAK:QXZPFV7_GW:+E!"P/I M$+\K=I&3=\^(?^'\U2Q^[E9^:#2PFFV5<4'UXXV5K*Z-)\W\=W#ZP6D,I^]7 M[YONN%K^"Y6LY/6?:J>.6FWH>SNVI^=:/?/+#S:<(3$.M[R6W:^W/4O%FZN) M[S7TO7]6;?>\]%]2,IC!!G@PP*/!R ,;1(-!]%V#>#"(/PSB3PV2P2 9#;+P M4P,R&!"+(>B#U85Z314M01! :14"1NEF&0#/_C@@N9034LIMEMYCCA#BQ"R;C0\/$H9OTI+?EYU:9 MO[W)[CA-WF,S?EC[)5JN^YGPPTV1G^B!_:+B4+72>^%*#S?="++G7#&M,KS3 M]^BHY^!Q4;.],J^I?A?]9-@O%#]=!]UQVB[^ U!+ P04 " 07[1("@]Y M6PL# #>#0 &0 'AL+W=OF*;M_&UZ+R]IE[K7@J3HK&M[VE6B=CN_7[CV[VU V2+3B=\4O_>S=&3K_+,3+\/%SMW;]H0^\ MYELY-%&JQRM_X'4]M*3(?Z=&WYE#Q?G[M?7O>KBJ^\]ESQ]$_:?:R:/JK>\Z M.[XOS[5\$IBN59QG:9\&Y]5JY^7\9^$3=5P!9HJ MT*U"X.N.CR#=S6^E+(N\$Q>G&^?V5 Y+R.Y(3<1V*-3CUO^ICO:J]+6@.,Z] MUZ&A2;,9-333L)O"4ZW?$(00&S*J4YS@!@+8QT W$,X;"*)%'T=-K#6MUL1) MFF08$T),:&+B=($Q-0%A1@09$6!D"X:IL3%BR(@_,5WQ5Z8K@9@$8);3E9B8 M.)YUY@,FA9@48)8S-FK2&8;8*L24#%(RDQ+Z"XJIL:W+D /(:[Y)2984(+)B M+)9F8#"TQ+ OS!F#QKYG!$#!$D0(E*06$DX !B(@#)DUMBRF0C;G8#=C9F;1!]F+LI2RW8B['@"CC>R M>!)]EH0M3\#R1AP3L'RVBFRSARU/R,W+L 0BVVX@['@"9C8R>1+-!Q3Y*]MX ML.4)N7F9RI,HFX$"!;(=M[#I"1P C%B>1.DG23@;"&2#$9&? MR@/_57:'JNV=9R'5+4"?U?="2*[ZHA;,=8[JLG7[J/E>#J^)>N_&Z\?X(<7I M>INZ7>F*_U!+ P04 " 07[1(-AUX+] ! #T! &0 'AL+W=O,,<]J+J,A][D45N1P-ZP6\**1'SJGZ M.55_<'%.[V/6AZ[X"U!+ P04 " 07[1( M6.TNL[H! =! &0 'AL+W=O<@.IYU'!, ;@]$LYLA[/ROUX1=/]3%)O07@4%G/0-UP@4?@W!,Y MX=\3YY>D3US.K^P_0[7._9D:>%3\G=6V,G,K,R?\JW:WJ[+[KI-F- MSAJ&W(C@Q?T)T&UXI@95:I"A*1;1N1,>2+C_+WA9]+2%9ZI;)@TZ*^M>4;CK M1BD+SDIZY[QTKE?G!8?&^FGNYCH^W[BPJK\VX_Q'*/\"4$L#!!0 ( !!? MM$@>BU>NJ0( 'T+ 9 >&PO=V]R:W-H965TR.//N312,2>>]KAJQ= LIV[GGB6W!:BIFO&6-NK/G74VEFG8'3[0= MHSL35%<>02CR:EHV;K8P:R]=MN!'694->^D<<:QKVOU;L8J?ERYV+PNOY:&0 M>L'+%MXU;E?6K!$E;YR.[9?N-SQ?$U]##.)WR<[B9NSHY#>TP.8? ]9@UAR!7CJ3ROR1(P66((@CL" M?R328V*#:0PF")'ZP3H^J.-/=5 XTNDQR8T.GI$05@E E0"H)H )0I @_#S- M//Q"FA&H$@%I6@ABD"#^_*GE\>2I883LCRT!A9(G]B/YPGZDH$H*E!.-5-)I M$Y+06HU^,4'61$ ]>.P[ )3$%AW+*P #%,E8!T]*BA]4!/L7 P9&XU: 0$EJ MT8']BP$#I[9487-BP)V39AI SW43ADV, 1=/^FD /=U0L),Q8.5I0T%^MS44 M;'@,.7[24%/+/VHHV/$8LORDH0"0M:%@SV/ ]"FV?+I@-Q/ J"FY3W4U@*+) M>] B!1N: (9.?0N%Y4L+F'"<;3Z [K)]T)4$-BN!S!J,I?SI!P*2\F[./2T] ML%^T.Y2-<#9CL.9=,<:*9,E6ASL+72<7V4@]C->[ZTV$_D;R]'':O M)^[L/U!+ P04 " 07[1(G0I]^E&UL[3WI;MS(F;_#IR@8"F(#5+L/=4N:3 ;0Y1E//)9BR3.;#?8' MFZQ6,\,F>WA(5I"GV 2[[^,GV^^H*A;)8G=+]F1W 0,9Q&JRKJ^^^^+715&* M*HU_J>195J7E'YZ-CZ?/Q(=5DA9_>+8LR_57+U\6X5*N@F*0K64*3Q99O@I* M^#._?5FLK($Z???-U$7_S=?G->196*YF6(D@C<9&6 M-Q$_)"EY;* ,9&,VD]_"/*!F(Q\ M,1Z.9MV'#P,Q.G8_-/LY<>ZG_;IZXYV\C8LR#V#NO#K.&@9[HSV$ >)/!*)#^(/\J'WEW>/*P[JXV&^W_J'7 E\SC#DT7B M/"@[8S7@O-_\Q@6=$Y@CHGE>)<%M^^DB2(K.C&=5GM. N CA2'^60=Z[^O[^ M:+P_&;5_?EWHFPC$3S))]G].L_M47,N@R%(9B==%4IMMFF>'[,$L#G( M'V!C27>P>?5W!5SN.LM+N#-Q7<(=%D(=J3WFSUTL5XK(JBQ)H"(;WWKVZ H4"K^#G MSH;_U %^>S1=H'/L698661)'<,Q(G 9)D(82M@>47XCG51I440Q/7@!)O[\^ M%\_W7G26DJ&AVFEG]O?OWEV\O1$GU]<7-]>=IT&Q)!9"_[CXI8KO@@1VW=GD M52[701P)^0%X5=&Y,61L7Q7K()1_> :?F M;K(20!&$IO7I^_$^<7KUZ?O;YQ7/M"PA8C43#Q[0T'PQ%>N0!T M QZ_#U/[PR']IP27"*IRF>7QWV0$< )^)6)D5Q%M+JNI%K "00@,.%P:T44O M 5G(U1P81"]I,$/HW=-TN'%3H[%_T'S:M\.RM;W?/V&QD7\XF^ZVV-:#GT3 M4D J ^H@.>['J0B#=0RHY,#N:E4QA49R$8=Q!TD9!8FK+D%&R[P /.AYM8V$ MXN3MN=@)A79EDL^O B2%I2QCX+K(-/?$RQY=",62)!X-"/0J3F'.&/E\5A!T MQ%].YJB.MK5MVO>W>K^O- M#9M]KZ]5-&[?7!L1_N5:YJ1B:K:U OFS!.D2WTGQ)BN*?KEI:[L=&@$U,UO) M>K$-V/ 6N/@UB$T'XR$MPK7PV]SW-Q5GBVZA*(.!>2L)>57[5?>@9 EIH*G MCN2=3++URJ%=78/B1WHSL'*)RC&^'T2K."7-NP0PN2DZZ^RA?Y<$YT6>K938 MJ/#'^F:ZL&59JF9\U3NGF$NP+J10]W03?.AN$(![%Q=(RO J2'!Z MLW2]B5>X9<&.<$:A3>\!3EK[8E%Y\*)S8V8- E1D#\_,<*,3P#8[\ :VEHNP M@>$)3+AIC(,>:/F>W??M>?.T?6\U3^R^1M"J61<'.CT-BCADV1TG5=EE(,T) M^V[@:5,^:M1/,KY=(C,Z -MK&T07VX4NK#V7;UH4\GR!SC3N5M MG*8(,R7J?7&R0@U9J3?];-LQ4EW(MI'(P1&D84,K5)2%\HQ4CA!8NM[,I\QP M[=9(&JI=F8EY%N216)$ZQP(.,+ZH$L"LLNC=QR-G<>^E(:S57,A&PUYKQKV; MQ\_CWL^Y,I*,Q0@',T % -MSL)!+DBRD-Q=!K!5MA 8(0D1%-)QH#RPA)/F9 MNCHB;AMY+O Z=JTIH>5B)(F#"5XP#W @\D9O6WM8C<4;A^W&-=#8?Y5D]QN4 M(^L=8K:UL#$06D@([,CXDZBOU:%,B(!TKD$ (Y1%,,^$@:L&JHIP_$^S)8PF3Y.N-; M%\\__N/TYC5L=-"S*>"Z!6G+:W+FF)V@B;.4WAJN.QP_TR!D,9)\6 %$J-5'Q? 7#&1RA%A\?FC+AH$ +J*A<07CG<-QX1N622 M !NO@@2V@-P6-@Y,(49AMT0 + !_4/T>B,NTZX7S:79U372F1!**P:_(?O,* MYB9# 8FH6,?I?E:5ZM#.XPXV8 5N-XU(X-*!*_$2WC[O PN)LUR*55$#Y8_,4720 H !!DR8:KD+ "S("'48;"KO#P''=P M1C@41HP : M8DLY0=&)X1 )C()GK:K7"U]&6BF_3&'0U#! J1SWNZ KTFM#% MYG@*H**MXN8HM:O_!!?-=>+)O-Q"FBAM&IUE4>+I'C MVC+-(PF):!(&28@&ET+>B&W+6O\"K.6M$-V#!D;;+2K$ !D"^N'U"GP.NXII M.%KXN%4B2&*UA5@SK&0T$">(3U[3P=U$]640B<,C_V VMHX[._2/#H_UJ7UQ MZ(^&4[&&&X1U <<5O!@Y5P%0FHD P.]**]+'1GID3T_AXM(P/8P!!,>S) ]J MSTVG_+2[Y]%LYA^,IO:FX12'DWK3X_'$A_^\)VY;/'+;[X"EI&7RX+WF&2V2 MN$:D FVS .H7K^0\KP#]O?HN7IU$#!O MV1CQV1XC0P&H]&](/46/^HI,&W!\PFY6#"\"&5S'1KV-.+. MC6X1+( QU5P:$0#F.1(DU620 W,+(KYI1/M57!*Z_[1$>\9&%5@53@A4)-'$ M5)JP#6)$4/TR&H]AR? UT\/=V\< F"R#.^37R'IR1"L^E@:!%O7_61#7-59> M S0,0$8ZXF^UJ20BMH19\A#H]3ZVWWO?_0QLC@@B &X,D%@=V'OR^5"#6Z#A M,$#,_CY(=T)LH.DZH/.ZYJ!?(0V9\^()?H##@O3LAH%.ZE.:'[TW%C["=HB# M;-W,L4\GTG;?/OL4[)_$\YML'8?B<'3TXBOQ>H5\01J6?P&:0O8@)?L ]D_) MI+T*'O %K^8!3FDX <%5GPF4\*@^^K<9)TT RN0=:U2-!EFZ<;BGAKM8ZJR) M^LA2Z3IA_#)@U7UO!&+@:,1"KQO%IE<.AU-_?#"A=U#0 F^I*.@5L$@C#E0C M-RM%7E,I0E1: W%@V@NHCW"<=1WB0+1>*RU/4856C^S("CN5FLJATHUD1>%& M6VWR6&EM$P9NI-:C2- 6U?RO2H 2&@U;O#&I\E]VC4>6K- ;# :''VC/2LPU6L5>D^Q"HML M4=XC W%;PK6Z2?9YCYV(9D"V(@T)GH'.L\ 4-3:1V6ZDI?]%EJ.G+$>QT7(D MI%:*C28:BY4#'F6P(00B42$^-G#3K@1U&MOO6_Q>V3+Y,Y(4#7ZJC:_4!F9>B8C0>R) MT>C(GQT>>XUD!#$;^Z/QD67[:!&!T?^+/C8V^' M- ,QGH[]\6SF]>47B(.#F7\\FWJNQ(+> A6VH%XX7%\7&WZ*\^992"> MCR=C?SB=P?N[19/WQ//9> QVW] LX0BJOV6?\DWPX2OO599+$.1*H0'TQPSG M0AGE-BM]/O+'AU.8]I%1>M[3Q#\\@,'BLG([PSQR>%4)T5JQSHBJ%TBCA@DQ M/EHZ '$CP"U",) K2M7/\K96MI$LO-'XY63T$F?'H1/UQ\S-?*? ?-\I=^L5 M9H$V_+0]0X#E]H]IZQ9GRR &1I0JJ2I.,2X#2OG%)?NK7UWZ8$#+-5R ^*,$ MTR25#R3G SL$4PO7F,T4%EVLQG+B'GI7F $@4["YEEA(R0XQO!5*@MT#!1D' M175V@,5"*%Z/OS=5:G(M*BL("$J%\>T K_@)=)8X6(DW _$.,0D7_1X,K%P^ M(!, ."C^ <(#V9,,8/Z12CU$!J'B4&G3C8H_R \AQ9LTSXMS$YC"FV_$F MT_HH^H%I7DY0\%JZXJ\ :]&"]:$_GFI8>RY8MQDU@'KO@ ;A3#@!KHH[G4O MDZ:^$J!'C%92"LZVI%2OEO^VC\?7Y]UDUUNQ"78BP/_WRA05';:Q82S!@)% C>X/WE ^^JRC%64^K?00"LBMHP:2[A:W<# IGY M7K9H>@%U"H5C='-IO%L?Q#>!/XX4.^1) 3U]^U5"D\8J*=O%^!OR:^>)77L8 MB/=K6$4'J#QVWM BB/F:P$><-TS:9!R6'-HAW['**4!B 48=W\8P=)8G(6T"1)T&X% M8(^#Y),7\:!>:3:"RI%DMV\3&ZQ47',]#5TI"AC+= MQ I59C)NL6YF72I?X4Q3=*G 5,8KV5#DVT&M0 MDM5#6R(#58<>&CR7;6XK-8>&6?Y3*S<&=LOAS[W18,C\4 7,M \ ^"IAA:>! MV247LT'BH63>D$U']PYO(CA*,B&T?LZI" L3OK51!UWK,KW%U#L8H?5\K\!0 M)F,@S<#^541P #K/%U-,//?-+<0HJ4F96&$0X&\JFM^R"@0Z+PSC,CX8F,D9)E)B+@SRG-PI%HXTL=XC M)$$P[8V/_>GQD7(?ME)NS"X M./9<"!>=:U)MWKB-X^K3ZF8,ZL(GL*H#O+R MOOS)>*K VK>=D^H6S!5<\* QBU6:]/R:?0-G+U#C6W"Y&ZLV2'61>5,K!?.' MOK@_;!?=EDR"&*IW6S:LOTI@K[07!P=AV-0H_'O@/>QH\["4R.Q)LR3R,2%0 MC-ZB#^4^M59;S%OFB5)<;+@A+8#J#Z0*6BU*A!9[V=/*MT/#!DP#R9[4$5VU MXFG?;3#A=1'4VQN!XGPTF0#&1"1-E01ATND>1.%J8:6'D80(4C ^$I'C.6 _ MH^%O?1:3S/(NPS)K^K%A'L7GS*NM9$V_W M+%Z0%)2.*($91W52GY4<<> ?3TUM%1C+Y7ZQ!G.WG3U&]X)R\H/,P[B0EFQL M;L2 M5AT)54?$Z]2:[?+)ZV[2%Y\BK MG5BKIC47S_=L)@OSS\;31[']#K-NV8.MK4S\\='1 -C^G?'Y;&/EWOG_85:N M.?DC&?GY3HS\O,/(FW#;@95_)DZ^D9'[D\D!'U4S\Q;4M [3X*%V-*'!]<\? MQ?51QP>K?B>N+SX/UQ_-!K-#9*W>5J[?.,MVKG\\?3S/]W;C^>+7XOE>_XE; M_%ELXOGLOWL*U_<>P_4=V_P\7-_;C>NW+?U/Y?KZ0-YYE^D376[5\T?^\?CP ML[!\KX?E'_2XV@\QSKE+I;9Z&P.;UNL?_]/4E>G,>KM.3->HJ'1OY89$J:\\ MQ 8N/')).\]33YNFFJB+G 8\T.%1.C9V2LU.#"S6+ M!I-CFH:/@1P?]W5"C^^=Z\(0U7)!%64I>%ZR^^(J"5(5!E=QF9*,5?36:!1ZG5@D M!$SR^R@5=*38P#X02;Q@5B-3%AQUOBAYJF^1"9O,VW:0P8K?3?S9:.AI!]4= MW!51$H)D4;& O*>44+7 MN,I&+/9@ZL\.)T^]S#H,QU-2?O=ZG6?#&!_[A=,)E9 P,.U.]YCUU M46F@51D,H[;B>4TQ3&*[D&9FK9JC1Q$6B2.CT1 ](_P,.H!XMJJG?ZF &:'V MA%)R8\ZYUHL)PF9E2_.KG:P-50^SY1068R�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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 64 166 1 false 25 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://trunity.co/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (unaudited) Sheet http://trunity.co/role/BalanceSheets Consolidated Balance Sheets (unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical) Sheet http://trunity.co/role/BalanceSheetsParenthetical Consolidated Balance Sheets (unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Unaudited Consolidated Statements of Operations and Comprehensive Loss Sheet http://trunity.co/role/UnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss Unaudited Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Unaudited Consolidated Statements of Changes in Stockholders' Deficit Sheet http://trunity.co/role/UnauditedConsolidatedStatementsOfChangesInStockholdersDeficit Unaudited Consolidated Statements of Changes in Stockholders' Deficit Statements 5 false false R6.htm 00000006 - Statement - Unaudited Consolidated Statements of Cash Flows Sheet http://trunity.co/role/UnauditedConsolidatedStatementsOfCashFlows Unaudited Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - Note 1 - Description of Business Sheet http://trunity.co/role/Note1-DescriptionOfBusiness Note 1 - Description of Business Notes 7 false false R8.htm 00000008 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://trunity.co/role/Note2-SummaryOfSignificantAccountingPolicies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Note 3 - Financial Condition and Going Concern Sheet http://trunity.co/role/Note3-FinancialConditionAndGoingConcern Note 3 - Financial Condition and Going Concern Notes 9 false false R10.htm 00000010 - Disclosure - Note 4 - Spin-Out and Discontinued Operations Sheet http://trunity.co/role/Note4-Spin-outAndDiscontinuedOperations Note 4 - Spin-Out and Discontinued Operations Notes 10 false false R11.htm 00000011 - Disclosure - Note 5 - Related Party Transactions Sheet http://trunity.co/role/Note5-RelatedPartyTransactions Note 5 - Related Party Transactions Notes 11 false false R12.htm 00000012 - Disclosure - Note 6 - Debt Sheet http://trunity.co/role/Note5-ConvertibleDebt Note 6 - Debt Notes 12 false false R13.htm 00000013 - Disclosure - Note 7 - Stockholders' Deficit Sheet http://trunity.co/role/Note7-StockholdersDeficit Note 7 - Stockholders' Deficit Notes 13 false false R14.htm 00000014 - Disclosure - Note 8 - Stock-Based Compensation Sheet http://trunity.co/role/Note8-Stock-basedCompensation Note 8 - Stock-Based Compensation Notes 14 false false R15.htm 00000015 - Disclosure - Note 9 - Warrants to Purchase Common Stock Sheet http://trunity.co/role/Note9-WarrantsToPurchaseCommonStock Note 9 - Warrants to Purchase Common Stock Notes 15 false false R16.htm 00000016 - Disclosure - Note 10 - Commitments and Contingencies Sheet http://trunity.co/role/Note10-CommitmentsAndContingencies Note 10 - Commitments and Contingencies Notes 16 false false R17.htm 00000017 - Disclosure - Note 11 - Subsequent Events Sheet http://trunity.co/role/Note11-SubsequentEvents Note 11 - Subsequent Events Notes 17 false false R18.htm 00000018 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Policies) Sheet http://trunity.co/role/Note2-SummaryOfSignificantAccountingPoliciesPolicies Note 2 - Summary of Significant Accounting Policies (Policies) Policies http://trunity.co/role/Note2-SummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Note 4 - Spin-Out and Discontinued Operations (Tables) Sheet http://trunity.co/role/Note4-Spin-outAndDiscontinuedOperationsTables Note 4 - Spin-Out and Discontinued Operations (Tables) Tables http://trunity.co/role/Note4-Spin-outAndDiscontinuedOperations 19 false false R20.htm 00000020 - Disclosure - Note 8 - Stock-Based Compensation (Tables) Sheet http://trunity.co/role/Note7-Share-basedCompensationTables Note 8 - Stock-Based Compensation (Tables) Tables http://trunity.co/role/Note8-Stock-basedCompensation 20 false false R21.htm 00000021 - Disclosure - Note 9 - Warrants to Purchase Common Stock (Tables) Sheet http://trunity.co/role/Note8-WarrantsToPurchaseCommonStockTables Note 9 - Warrants to Purchase Common Stock (Tables) Tables http://trunity.co/role/Note9-WarrantsToPurchaseCommonStock 21 false false R22.htm 00000022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Narrative) Sheet http://trunity.co/role/Note2-SummaryOfSignificantAccountingPoliciesDetailsNarrative Note 2 - Summary of Significant Accounting Policies (Details Narrative) Details http://trunity.co/role/Note2-SummaryOfSignificantAccountingPoliciesPolicies 22 false false R23.htm 00000023 - Disclosure - Note 3 - Financial Condition and Going Concern (Details Narrative) Sheet http://trunity.co/role/Note3-FinancialConditionAndGoingConcernDetailsNarrative Note 3 - Financial Condition and Going Concern (Details Narrative) Details http://trunity.co/role/Note3-FinancialConditionAndGoingConcern 23 false false R24.htm 00000024 - Disclosure - Note 4 - Spin-Out and Discontinued Operations (Details) Sheet http://trunity.co/role/Note4-Spin-outAndDiscontinuedOperationsDetails Note 4 - Spin-Out and Discontinued Operations (Details) Details http://trunity.co/role/Note4-Spin-outAndDiscontinuedOperationsTables 24 false false R25.htm 00000025 - Disclosure - Note 5 - Related Party Transactions (Details Narrative) Sheet http://trunity.co/role/Note5-RelatedPartyTransactionsDetailsNarrative Note 5 - Related Party Transactions (Details Narrative) Details http://trunity.co/role/Note5-RelatedPartyTransactions 25 false false R26.htm 00000026 - Disclosure - Note 6 - Debt (Details Narrative) Sheet http://trunity.co/role/Note6-DebtDetailsNarrative Note 6 - Debt (Details Narrative) Details http://trunity.co/role/Note5-ConvertibleDebt 26 false false R27.htm 00000027 - Disclosure - Note 7 - Stockholders' Deficit (Details Narrative) Sheet http://trunity.co/role/Note7-StockholdersDeficitDetailsNarrative Note 7 - Stockholders' Deficit (Details Narrative) Details http://trunity.co/role/Note7-StockholdersDeficit 27 false false R28.htm 00000028 - Disclosure - Note 8 - Stock-Based Compensation (Details) Sheet http://trunity.co/role/Note8-Stock-basedCompensationDetails Note 8 - Stock-Based Compensation (Details) Details http://trunity.co/role/Note7-Share-basedCompensationTables 28 false false R29.htm 00000029 - Disclosure - Note 8 - Stock-Based Compensation (Details Narrative) Sheet http://trunity.co/role/Note8-Stock-basedCompensationDetailsNarrative Note 8 - Stock-Based Compensation (Details Narrative) Details http://trunity.co/role/Note7-Share-basedCompensationTables 29 false false R30.htm 00000030 - Disclosure - Note 9 - Warrants to Purchase Common Stock (Details) Sheet http://trunity.co/role/Note9-WarrantsToPurchaseCommonStockDetails Note 9 - Warrants to Purchase Common Stock (Details) Details http://trunity.co/role/Note8-WarrantsToPurchaseCommonStockTables 30 false false R31.htm 00000031 - Disclosure - Note 9 - Warrants to Purchase Common Stock (Details Narrative) Sheet http://trunity.co/role/Note9-WarrantsToPurchaseCommonStockDetailsNarrative Note 9 - Warrants to Purchase Common Stock (Details Narrative) Details http://trunity.co/role/Note8-WarrantsToPurchaseCommonStockTables 31 false false R32.htm 00000032 - Disclosure - Note 10 - Commitments and Contingencies (Details Narrative) Sheet http://trunity.co/role/Note10-CommitmentsAndContingenciesDetailsNarrative Note 10 - Commitments and Contingencies (Details Narrative) Details http://trunity.co/role/Note10-CommitmentsAndContingencies 32 false false R33.htm 00000033 - Disclosure - Note 11 - Subsequent Events (Details Narrative) Sheet http://trunity.co/role/Note11-SubsequentEventsDetailsNarrative Note 11 - Subsequent Events (Details Narrative) Details http://trunity.co/role/Note11-SubsequentEvents 33 false false All Reports Book All Reports tntyob-20160331.xml tntyob-20160331.xsd tntyob-20160331_cal.xml tntyob-20160331_def.xml tntyob-20160331_lab.xml tntyob-20160331_pre.xml true true ZIP 50 0001575705-16-000133-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001575705-16-000133-xbrl.zip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end